[{"data":1,"prerenderedAt":1140},["Reactive",2],{"endpoints.content.index/news-and-stories/interview-with-dr-ram-shankar-advancing-virus-free-gene-therapies-with-minicircle-dna/":3},[4,31,55,86,168,203,228,251,274,301,327,370,416,441,470,494,524,555,580,614,644,675,717,761,796,838,872,911,946,972,1004,1030,1072,1115],{"type":5,"title":6,"slug":9,"place":11,"description":12,"date":14,"links":15,"claim":16,"content":17},"Story",{"de":7,"en":8},"","Interview with Dr. Ram Shankar: Advancing Virus-Free Gene Therapies with Minicircle DNA",{"de":7,"en":10},"interview-with-dr-ram-shankar-advancing-virus-free-gene-therapies-with-minicircle-dna",{"de":7,"en":7},{"de":13,"en":8},"Interview with Head of GMP - A Conversation on GMP DNA Manufacturing for Next-Generation Gene Therapies","2026-04-14",[],{"de":7,"en":7},[18],{"headline":19,"subline":21,"description":22,"text":23,"images":25,"files":30},{"de":7,"en":20},"“Minicircle DNA removes everything that is unnecessary for therapy, resulting in a cleaner, safer, and more efficient vector.”",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":24},"\u003Cp>\u003Cstrong>Interview with Dr. Ram Shankar, Chief Scientific Officer, PlasmidFactory GmbH\u003C/strong>\u003C/p>\u003Cp>PlasmidFactory GmbH, based in Bielefeld, Germany, is recognized as a leading CDMO for the production of plasmid and Minicircle DNA. Over the past 25 years, the company has evolved from a small academic spin-off into a global reference for DNA manufacturing in gene and cell therapy. Following the launch of its new GMP facility and the clinical success of several Minicircle-based therapies, PlasmidFactory is entering a new phase expanding its impact from plasmid DNA manufacturing toward next-generation, virus-free gene delivery.\u003Cbr>Dr. Ram Shankar, Chief Scientific Officer at PlasmidFactory, shares his insights into the company’s latest developments and the growing importance of Minicircle technology in cell and gene therapy.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>You recently presented data on Minicircle-based CAR-T cells at the CAR-TCR Summit in Boston. What makes Minicircles such a breakthrough for gene and cell therapy?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>Minicircles represent the logical next step in non-viral gene transfer. Traditional plasmids contain bacterial backbone sequences like origins of replication, antibiotic resistance genes, and other elements that are not only unnecessary for therapy but can also compromise safety and performance. Minicircles remove these bacterial sequences entirely, leaving only the therapeutic expression cassette in a small, supercoiled DNA molecule.\u003C/p>\u003Cp>This design has profound advantages: higher transfection efficiency, stronger and more stable expression, and significantly lower cytotoxicity. Because there are no bacterial genes, the risk of immune activation or gene silencing is minimized. The result is a cleaner, safer, and more efficient DNA vector that is ideally suited for advanced therapies such as CAR-T, TCR-T, or TIL approaches.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>How do Minicircles address some of the limitations of viral vectors, such as lentivirus?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>Viral vectors have enabled the first wave of gene therapies, but they come with several drawbacks liek complex production, high cost, limited payload capacity, and concerns around insertional mutagenesis. Minicircles, in combination with transposon systems like Sleeping Beauty or PiggyBac, offer a virus-free alternative that is scalable, cost-effective, and safer.\u003C/p>\u003Cp>As shown by Monjezi and colleagues in 2016 and later confirmed by Díez et al. in 2025, CAR-T cells engineered with Minicircle DNA and Sleeping Beauty transposase mRNA achieved potent anti-tumor activity while integrating preferentially into genomic safe-harbor regions. In the 2016 study, Sleeping Beauty integrations occurred roughly six times more often in defined genomic safe harbors as described by Monjezi et al. as “more than 50 kilobases from transcription start sites and several hundred kilobases from cancer-related genes”, compared with lentiviral vectors. This indicates a more favorable integration profile and potentially improved genomic safety.\u003C/p>\u003Cp>Moreover, the production of Minicircles is much faster and more economical, requiring no complex viral packaging or higher biosafety-level infrastructure.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>Several clinical programs already use Minicircles. Could you share some examples?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>Yes, Minicircles produced at PlasmidFactory have already entered multiple clinical trials, including \u003Cem>CARAMBA\u003C/em>, \u003Cem>TranspoCART19\u003C/em>, and \u003Cem>LION-1\u003C/em>. These programs explore virus-free CAR-T cell generation using transposon systems and hopefully demonstrate strong efficacy and favorable safety profiles.\u003C/p>\u003Cp>Our technology has therefore moved well beyond proof-of-concept. It is clinically validated and now ready for late-stage development and commercial translation. We are proud that Minicircle DNA produced by PlasmidFactory contributes directly to these pioneering studies, demonstrating that virus-free engineering is not only possible, but it is the future.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>What role does manufacturing quality play in enabling this transition from research to clinic?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>Manufacturing quality is absolutely central to what we do. For 25 years, PlasmidFactory has set the benchmark for high-purity DNA. We offer three quality grades (Research, High Quality (HQ), and GMP) to ensure a seamless transition from early discovery to clinical and commercial production.\u003C/p>\u003Cp>Our new GMP facility in Bielefeld, which will be soon fully operational allows us to produce both plasmid and Minicircle DNA at large scale using single-use equipment and rigorous quality controls. To avoid any risk of cross-contamination each product is made under strict segregation - only one plasmid or Minicircle is produced per suite.\u003C/p>\u003Cp>Our proprietary purification process delivers DNA with extremely high supercoiled (ccc) content and minimal impurities. These standards meet or exceed current regulatory expectations for advanced therapy starting materials.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>PlasmidFactory’s Minicircle technology is patented. How does it differ from other vector systems available today?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>The uniqueness lies both in the molecular design and in the process. Our patented system produces Minicircles by intramolecular recombination from a well-characterized parental plasmid. During the process, the bacterial backbone forms a miniplasmid that is efficiently removed during purification, leaving only the therapeutic Minicircle DNA.\u003C/p>\u003Cp>The method is robust, scalable, and license-free for our clients, which is an important advantage. It also allows the production of complex constructs without cargo limitations, supporting polycistronic designs or regulatory elements for fine-tuned expression. Because the same platform is compatible with both research-grade and GMP manufacturing, our customers can easily scale their programs without changing the vector backbone or process.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>Beyond CAR-T, where else do you see Minicircle DNA having impact?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>The potential applications are vast. Besides CAR-T and TCR-T cells, we see strong interest in AAV production and RNA manufacturing, where Minicircle DNA could serve as a cleaner, more efficient template compared to conventional plasmids. It eliminates unwanted bacterial sequences, improving both safety and productivity of viral and non-viral vector production processes.\u003C/p>\u003Cp>Beyond these, Minicircles are also gaining attention in natural killer (NK) cell engineering, induced pluripotent stem cells, hematopoietic stem and progenitor cells, as well as \u003Cem>in vivo\u003C/em> gene delivery. A particularly exciting frontier is direct \u003Cem>in vivo\u003C/em> immune-cell engineering, where Minicircles can be formulated with lipid or polymer nanoparticles (LNPs/PNPs) for systemic, non-viral gene transfer. This could one day enable in vivo generation of CAR-T or TIL cells, avoiding the need for complex ex vivo manufacturing entirely.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>What trends do you observe in the broader CDMO landscape for DNA manufacturing?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>We are witnessing an evolution from conventional plasmid production toward specialized DNA formats tailored for advanced therapies with Minicircles being a prime example. Sponsors now require CDMOs that not only manufacture DNA but also understand the underlying biology and regulatory context.\u003C/p>\u003Cp>At PlasmidFactory, we combine 25 years of manufacturing experience with deep scientific expertise. Our scientists work closely with clients from vector design through analytical characterization, ensuring that the DNA meets both functional and regulatory requirements. With over 3,500 constructs produced and a 99.9 percent success rate, we offer a level of reliability and know-how that few others can match.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>You have recently strengthened your global partnerships. How important is international collaboration, particularly in Asia and India?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>It is very important. India has a rapidly growing biotechnology and vaccine industry with strong interest in RNA and DNA technologies. Together with our local partner, \u003Cstrong>Dr. Nagaraj Rao of RRR Labs, Navi Mumbai\u003C/strong>, we are building bridges between German DNA manufacturing expertise and India’s dynamic biopharma ecosystem.\u003C/p>\u003Cp>This partnership supports Indian researchers and developers by giving them access to the same high-quality DNA, both plasmid and Minicircle, that leading global companies use for their advanced therapy programs. We see great potential for collaboration in the areas of CAR-T development, RNA therapeutics, and DNA vaccine research.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>From a scientific point of view, what are your priorities for R&D at PlasmidFactory?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>Our R&D covers the entire DNA production chain – from strain and construct optimization to upstream bioprocessing, purification, and analytical control. We focus on process innovation, plasmid stability, and quality assurance, continuously refining fermentation, purification, and single-use technologies to maximize yield and purity. A key area is the development of next-generation vectors, including non-viral and resistance-gene-free systems such as Minicircles, and their application in AAV and RNA production.\u003C/p>\u003Cp>We also investigate plasmid stability under various storage and processing conditions and advance analytical methods such as capillary gel electrophoresis (CGE) and next-generation sequencing (NGS) to ensure precise quality control. At PlasmidFactory, innovation means combining scientific rigor with practical application, ensuring every new development enhances our ability to deliver the highest-quality DNA for research, clinical, and GMP use.\u003C/p>\u003Chr>\u003Cp>\u003Cstrong>Finally, where do you see the future of PlasmidFactory and of Minicircle technology in the next five years?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Dr. Ram Shankar:\u003C/strong>\u003Cbr>We believe that Minicircle DNA will become a cornerstone of modern gene and cell therapy, complementing both viral and non-viral approaches. As the industry continues to diversify beyond traditional vector systems, the demand for safe, efficient, and scalable DNA starting materials will grow rapidly. PlasmidFactory is ready for that future with proven technology, GMP capacity, and a passionate team dedicated to advancing the science of DNA manufacturing.\u003C/p>\u003Cp>In the next five years, we expect to see Minicircles playing an important role not only in ex-vivo CAR-T and transposon-based programs, but also as templates for viral and non-viral vector production, as well as in emerging \u003Cem>in vivo\u003C/em> applications using LNP-based delivery. This will further broaden the possibilities for gene and cell therapies, making them simpler, safer, and more accessible to patients worldwide.\u003C/p>\u003Cp>At PlasmidFactory, our mission remains clear: to provide the cleanest, most reliable DNA possible and to empower researchers and developers to turn genetic ideas into life-saving therapies. DNA is, quite literally, in our DNA.\u003C/p>",[26],{"url":27,"alt":28},"https://api.plasmidfactory.com/storage/275/responsive-images/2026-04-01-Ram-F%26E-web___webp_W___WIDTH____H.webp",{"de":7,"en":29},"Dr. Ram Shankar - Chief Scientific Officer, PlasmidFactory GmbH",[],{"type":5,"title":32,"slug":34,"place":36,"description":37,"date":38,"links":39,"claim":40,"content":41},{"de":7,"en":33},"A Conversation on GMP DNA Manufacturing for Next-Generation Gene Therapies",{"de":7,"en":35},"interview-on-gmp-dna-manufacturing-for-next-generation-gene-therapies",{"de":7,"en":7},{"de":13,"en":13},"2026-02-17",[],{"de":7,"en":7},[42],{"headline":43,"subline":45,"description":46,"text":47,"images":49,"files":54},{"de":7,"en":44},"“Building GMP DNA Manufacturing to Support Therapies of Tomorrow”",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":48},"\u003Cp>\u003Cstrong>Interview with Florian Weber, Head of GMP Production, PlasmidFactory GmbH\u003C/strong>\u003C/p>\u003Cp>PlasmidFactory GmbH, based in Bielefeld, Germany, has supported scientists for more than 25 years as a specialized CDMO for plasmid and Minicircle DNA. As the only provider worldwide offering GMP-grade Minicircle DNA, the company plays a unique role supporting advanced cell & gene therapy as well as vaccine-related development, and its DNA is already used in several clinical programs.\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>Expectations toward DNA manufacturing have changed significantly in recent years. What developments made a purpose-built GMP facility necessary?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Florian Weber:\u003C/strong>\u003Cbr>Gene and cell therapy has matured. What used to be highly experimental is now moving through structured clinical development and expectations toward DNA as starting material have evolved accordingly.\u003C/p>\u003Cp>We see more virus-free engineering concepts, higher doses for \u003Cem>in vivo\u003C/em> settings, and an overall push toward scalability and reliability. That changes what GMP really needs to deliver. It’s no longer just about meeting formal requirements; it’s about providing a manufacturing platform that developers can rely on long-term.\u003C/p>\u003Cp>Instead of adapting legacy infrastructure, we built a dedicated GMP facility specifically for plasmid and Minicircle DNA production. It includes clearly separated process areas and a fully end-to-end single-use workflow designed to prevent cross-contamination and support consistent product quality across batches and programs.\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>Which design or process decisions have the greatest impact on robustness and product quality in daily operation?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Florian Weber:\u003C/strong>\u003Cbr>Robustness starts with focus. We have been manufacturing DNA for more than 25 years and that specialization shows in how our processes are structured.\u003C/p>\u003Cp>One key element is our fully single-use manufacturing concept combined with controlled cleanroom environments and pharmaceutical-grade utilities such as qualified water systems to create a stable, predictable production setting. These features support consistent quality, regulatory compliance, and suitability for late clinical and commercial supply.\u003C/p>\u003Cp>Equally important is vertical integration. Core manufacturing and analytical steps are performed in-house under GMP conditions, including comprehensive quality control and in-house QP batch release. This tight integration between production and QC means we can react quickly, maintain transparency, and support customers proactively especially when programs evolve or regulatory questions arise.\u003C/p>\u003Cp>For advanced therapies, this level of control isn’t a luxury - it’s essential.\u003C/p>\u003Cp>\u003Cstrong>Quality control is often discussed mainly in the context of compliance. From your experience, what role does integrated QC play in supporting next-generation cell & gene therapy programs?\u003C/strong>\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>Florian Weber:\u003C/strong>\u003Cbr>For virus-free cell modification approaches, DNA is not just a raw material - it becomes a defining component of the therapeutic strategy.\u003C/p>\u003Cp>In these settings, purity, topology, and residual impurities directly influence performance and safety. That’s why we view QC not as a regulatory hurdle, but as a scientific tool. Close integration between analytics and manufacturing allows us to monitor critical quality attributes continuously and ensure that what leaves our facility performs as expected in demanding biological systems.\u003C/p>\u003Cp>This is particularly relevant for Minicircle DNA. At the process level, Minicircles can reduce the DNA burden per application: their compact, backbone-free structure supports strong expression with lower DNA input, which can translate into reduced transfection stress, improved reproducibility, and lower downstream variability. In addition, simplified DNA architectures - particularly in workflows such as virus-free cell therapy or AAV production - streamline processes and ease analytical and QC demands, contributing to more efficient and cost-conscious manufacturing.\u003C/p>\u003Cp>The fact that GMP-grade Minicircle DNA is already being used in ongoing clinical trials demonstrates that this approach is not theoretical - it performs under real clinical conditions.\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>PlasmidFactory is the only provider offering GMP-grade Minicircle DNA. Why does that matter for developers?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Florian Weber:\u003C/strong>\u003Cbr>Minicircle DNA is not just a smaller plasmid. It is a different molecular concept: streamlined, backbone-free, and designed for performance in sensitive cells and demanding applications.\u003C/p>\u003Cp>For developers pursuing virus-free cell engineering or looking for cleaner starting material for vector or mRNA production, this difference becomes meaningful. It can improve transfection efficiency, reduce unwanted bacterial elements, and support regulatory clarity around starting material purity.\u003C/p>\u003Cp>Bringing Minicircles into GMP required long-term expertise in DNA process development, purification, and analytics. It builds on more than two decades of focused DNA manufacturing and today, it allows customers to move from early research through clinical supply without changing vector formats or manufacturing partners.\u003C/p>\u003Cp>That continuity reduces risk and increases safety - scientifically and strategically.\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>Your key message to developers moving toward the clinic?\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Florian Weber:\u003C/strong>\u003Cbr>Think about GMP earlier than you think you need to.\u003C/p>\u003Cp>DNA decisions made at research stage (e.g. vector format, backbone elements, production platform) influence scalability, safety assessments, and regulatory discussions later on. Working with a specialized DNA manufacturer from the beginning helps avoid painful transitions.\u003C/p>\u003Cp>Our role is to provide a stable and scientifically sound manufacturing foundation. With 25 years of focused DNA manufacturing experience, a dedicated GMP environment, and a unique Minicircle platform already supporting clinical programs, we see ourselves as a long-term partner for therapies designed to reach patients, not just proof-of-concept milestones.\u003C/p>",[50],{"url":51,"alt":52},"https://api.plasmidfactory.com/storage/265/responsive-images/2026-02-18-Florian-GMP___webp_W___WIDTH____H.webp",{"de":7,"en":53},"Head of GMP - Florian Weber",[],{"type":56,"title":57,"slug":59,"place":61,"description":62,"date":64,"links":65,"claim":66,"content":68},"News",{"de":7,"en":58},"25% Discount Offer on In-Stock Products",{"de":7,"en":60},"discount-offer-on-in-stock-products",{"de":7,"en":7},{"de":63,"en":58},"25% Discount Offer on InStock Products","2026-01-29",[],{"de":7,"en":67},"Save 25% on In-Stock DNA Products",[69],{"headline":70,"subline":72,"description":73,"text":74,"images":76,"files":81},{"de":7,"en":71},"In Stock. Ready to Ship. 25% Off.",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":75},"\u003Cp>\u003Cstrong>Get 25% OFF all In-Stock DNA Products\u003C/strong> (preproduced plasmid and Minicircle DNA available off-the-shelf for immediate delivery)\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>Limited Time Offer: February 1 – April 30\u003C/strong>\u003Cbr>\u003Cstrong>Promo Code: PFINSTOCK25\u003C/strong>\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>In-Stock DNA Products Include:\u003C/strong>\u003C/p>\u003Cul>\u003Cli>\u003Cp>• \u003Cstrong>Plasmids & Minicircles for AAV production\u003C/strong>\u003Cbr>Plasmids and Minicircles containing both helper and packaging functions as well as a vector plasmids and Minicircles for the production of various AAV serotypes. \u003Cbr>→ \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/stock-dna/plasmids-minicircles-for-aav-production/\" tt-mode=\"url\">More Information\u003C/a>\u003C/p>\u003C/li>\u003C/ul>\u003Cp>\u003C/p>\u003Cul>\u003Cli>\u003Cp>• \u003Cstrong>Molecular Size Markers\u003C/strong>\u003Cbr>Lyophilized DNA ladders with different size ranges for the analysis of short and long fragments - loading buffer included.\u003Cbr>→ \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/stock-dna/molecular-size-marker/\" tt-mode=\"url\">More Information\u003C/a>\u003C/p>\u003C/li>\u003C/ul>\u003Cp>\u003C/p>\u003Cul>\u003Cli>\u003Cp>• \u003Cstrong>Reporter Constructs and pEPito plasmids\u003C/strong>\u003Cbr>Plasmids and Minicircles with different reporter genes for transfection optimization as well as pEPito plasmids with S/MAR elements to stabilize gene expression\u003Cbr>→ \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/stock-dna/reporter-constructs-and-pepito-plasmids/\" tt-mode=\"url\">More Information\u003C/a>\u003C/p>\u003C/li>\u003C/ul>\u003Cp>\u003C/p>\u003Cp>\u003Cstrong>How to Request a Quote with the Discount\u003C/strong>\u003C/p>\u003Cp>Use the quote form for specific quantities: \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/#get-in-touch\" tt-mode=\"url\">Quote Form\u003C/a>\u003C/p>\u003Col>\u003Cli>\u003Cp>1. Click \u003Cstrong>“I would like a specific quote for the following product”\u003C/strong>\u003C/p>\u003C/li>\u003Cli>\u003Cp>2. Choose product and amount\u003C/p>\u003C/li>\u003Cli>\u003Cp>3. Add Promo Code \u003Cstrong>PFINSTOCK25\u003C/strong>\u003C/p>\u003C/li>\u003C/ol>\u003Cp>Or directly contact: \u003Ca target=\"_blank\" href=\"mailto:contact@plasmidfactory.com\" tt-mode=\"url\">\u003Cstrong>contact@plasmidfactory.com\u003C/strong>\u003C/a>\u003C/p>\u003Cp>Available for a limited time while supplies last.\u003C/p>",[77],{"url":78,"alt":79},"https://api.plasmidfactory.com/storage/260/responsive-images/-Instock-1920x1600-Composing___webp_W___WIDTH____H.webp",{"de":7,"en":80},"25% OFF all In-Stock Products",[82],{"file":83,"title":84},"https://api.plasmidfactory.com/storage/261/InStockDiscountOffer-Aktion-Flyer-A4-0126-final-digital.pdf",{"de":7,"en":85},"In-Stock Discount Offer - Flyer",{"type":56,"title":87,"slug":89,"place":91,"description":92,"date":95,"links":96,"claim":105,"content":106},{"de":7,"en":88},"Improve Your AAV Manufacturing Efficiency & Safety",{"de":7,"en":90},"improve-your-aav-manufacturing-efficiency-and-safety",{"de":7,"en":7},{"de":93,"en":94},"Minicircle DNA reduziert plasmidbedingte Verunreinigungen in der AAV-Herstellung. Verbessern Sie Vektorqualität, Sicherheit und GMP-Skalierbarkeit durch ba","Minicircle DNA reduces plasmid-derived impurities in AAV manufacturing. Improve vector quality, safety, and GMP scalability with backbone-free DNA formats.","2026-01-28",[97,101],{"title":98,"target":100},{"de":7,"en":99},"Buddle et al. Case Report, 2026","https://www.nature.com/articles/s41591-025-04073-z",{"title":102,"target":104},{"de":7,"en":103},"Schnoedt et al., Mol Ther Nucleic Acids. 2016","https://pubmed.ncbi.nlm.nih.gov/28131313/",{"de":7,"en":7},[107,116,133,146,159],{"headline":108,"subline":110,"description":111,"text":112,"images":114,"files":115},{"de":7,"en":109},"Why DNA Impurities Are Moving Into Focus",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":113},"\u003Cp>A recent clinical case report (\u003Ca target=\"_blank\" href=\"https://www.nature.com/articles/s41591-025-04073-z\" tt-mode=\"url\">Buddle et al., \u003Cem>Nature Medicine\u003C/em>\u003C/a>) described prolonged, severe hepatitis following systemic AAV therapy. Beyond known vector-related risks, investigators identified \u003Cstrong>plasmid backbone DNA in ~5–6% of hepatocytes\u003C/strong>.\u003C/p>\u003Cp>These sequences originated from bacterial plasmids used during AAV manufacturing and may include:\u003C/p>\u003Cul>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>Origins of replication\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>Antibiotic resistance genes\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>Other non-therapeutic backbone elements\u003C/p>\u003C/li>\u003C/ul>\u003Cp>Traditionally classified as \u003Cstrong>process-related impurities\u003C/strong>, such DNA fragments may have \u003Cstrong>biological relevance\u003C/strong>, as liver toxcity and hepatitis, particularly in high-dose systemic applications where immune activation is a key safety concern. The key question is shifting from \u003Cem>“Are impurities within specification?”\u003C/em> to \u003Cem>“What biological impact might they have?”\u003C/em>\u003C/p>\u003Chr>\u003Ch3>\u003Cstrong>How Backbone-free Minicircles Shift the Paradigm\u003C/strong>\u003C/h3>\u003Cp>\u003Ca target=\"_blank\" href=\"https://pubmed.ncbi.nlm.nih.gov/28131313/\" tt-mode=\"url\">Schnoedt et al. (2017)\u003C/a> showed that bacterial backbone sequences are difficult to fully remove during plasmid-based AAV manufacturing and that residual fragments can persist through purification and be unintentionally packaged into AAV capsids, reducing yield and efficiency. This highlights the limits of downstream purification in conventional transfection workflows.\u003C/p>\u003Cp>Minicircle DNA addresses this challenge at the source. As backbone-free, circular supercoiled DNA molecules containing only the expression cassette, minicircles provide:\u003C/p>\u003Cp>\u003Cstrong>• \u003C/strong>No bacterial backbone sequences in the starting material\u003Cbr>\u003Cstrong>• \u003C/strong>Elimination of backbone-packaging into AAV particles\u003Cbr>\u003Cstrong>• \u003C/strong>Impurity reduction by design rather than purification alone\u003C/p>\u003Cp>This shifts the strategy \u003Cstrong>from downstream removal to upstream prevention\u003C/strong>, lowering back-packaging risk and enabling cleaner AAV preparations. This is particularly relevant for high-dose systemic applications and late-stage programs with strict safety and regulatory expectations.\u003C/p>",[],[],{"headline":117,"subline":119,"description":120,"text":121,"images":123,"files":128},{"de":7,"en":118},"Why Minicircle DNA Is a Strategic Lever for AAV Vector Manufacturing, Yield & Quality",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":122},"\u003Ch3>\u003Cstrong>Performance and Scalability\u003C/strong>\u003C/h3>\u003Cp>\u003Cspan>The small, backbone-free, supercoiled \u003C/span>\u003Cstrong>\u003Cspan>Minicircle DNA format is optimized for AAV production\u003C/span>\u003C/strong>\u003Cspan> and translates structural DNA advantages into higher functional yields and improved vector safety.\u003C/span>\u003C/p>\u003Cp>\u003C/p>\u003Cul>\u003Cli>\u003Cp>\u003Cstrong>• \u003Cspan>Improved producer cell transfection and downstream transduction\u003C/span>\u003C/strong>\u003Cbr>\u003Cspan>Due to their compact, supercoiled structure, minicircles support more efficient transfection of AAV producer cells, leading to improved virus quality. This translates into \u003C/span>\u003Cstrong>\u003Cspan>up to ~30% higher transduction efficiency\u003C/span>\u003C/strong>\u003Cspan> in target cells, reflecting improved functionality of the produced vectors rather than changes in the target cells.\u003C/span>\u003C/p>\u003Cp>\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003Cspan>Higher functional titers and full capsid rates\u003C/span>\u003C/strong>\u003Cbr>\u003Cspan>The absence of bacterial backbone sequences enables more efficient genome processing and encapsidation during AAV assembly. This results in a higher proportion of correctly packaged, full capsids and a strong increase in functional AAV particle output. Minicircle-based AAV production has been reported to deliver \u003C/span>\u003Cstrong>\u003Cspan>3–4× higher functional titers\u003C/span>\u003C/strong>\u003Cspan> compared to conventional plasmid formats\u003C/span>\u003C/p>\u003Cp>\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003Cspan>Enhanced safety and reduced impurity burden\u003C/span>\u003C/strong>\u003Cbr>\u003Cspan>Because minicircles are backbone-free by design, they eliminate a major source of plasmid-derived DNA impurities and reduce the risk of unintended backbone packaging into AAV particles. This supports cleaner virus preparations and may simplify downstream purification and control strategies.\u003C/span>\u003C/p>\u003C/li>\u003C/ul>\u003Cp>Together, these properties make DNA format selection a strategic factor for balancing \u003Cstrong>safety, manufacturability, and scalability \u003C/strong>in advanced AAV programs.\u003C/p>",[124],{"url":125,"alt":126},"https://api.plasmidfactory.com/storage/255/responsive-images/AAV-Flyer-Product-Bild-Website___webp_W___WIDTH____H.webp",{"de":7,"en":127},"Boosting AAV Production with Minicircle - Flyer",[129],{"file":130,"title":131},"https://api.plasmidfactory.com/storage/253/Flyer-AAV_MC.pdf",{"de":7,"en":132},"Boosting AAV Production with Minicircles - Flyer",{"headline":134,"subline":136,"description":137,"text":138,"images":140,"files":145},{"de":7,"en":135},"How Can Minicircle DNA Upgrade AAV Manufacturing Without Platform Disruption?",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":139},"\u003Cp>Minicircle DNA can be integrated into established AAV production workflows with minimal changes to existing processes — supported by \u003Cstrong>PlasmidFactory’s EU-based \u003C/strong>\u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/news-and-stories/gmp-manufacturing-for-plasmid-and-minicircle-dna/\" tt-mode=\"url\">\u003Cstrong>GMP manufacturing capabilities\u003C/strong>\u003C/a> from early development to large-scale production.\u003C/p>\u003Ch3>\u003Cstrong>Flexible implementation models\u003C/strong>\u003C/h3>\u003Cp>Depending on platform strategy, serotype, and development stage, different DNA format and manufacturing approaches can be applied — with or without Minicircle integration.\u003C/p>\u003Cp>\u003Cstrong>Option 1 — Optimized system approach\u003C/strong>\u003Cbr>Adopt PlasmidFactory's fully optimized proprietary \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/stock-dna/plasmids-minicircles-for-aav-production/\" tt-mode=\"url\">2-plasmid or 2-Minicircle-based production systems\u003C/a>.\u003C/p>\u003Cp>\u003Cstrong>Option 2 — Incremental upgrade\u003C/strong>\u003Cbr>Integrate Minicircles into existing 2- or 3-plasmid AAV workflows by replacing only the transfer vector.\u003C/p>\u003Cp>\u003Cstrong>Option 3 — Design conversion\u003C/strong>\u003Cbr>Convert existing AAV plasmid constructs into backbone-free Minicircle formats.\u003C/p>\u003Cp>\u003Cstrong>Option 4 — Amplification of established plasmid systems\u003C/strong>\u003Cbr>Continue with your conventional AAV plasmid-based setup and scale production from research to clinical and commercial supply under GMP conditions.\u003C/p>\u003Cp>All options can be combined with our innovative \u003Cspan>ITRRESCUE®\u003C/span> & ITRPROTECT® technologies to optimize vector performance.\u003C/p>\u003Chr>\u003Cp>This flexibility allows developers to align \u003Cstrong>DNA format choice, risk profile, and GMP pathways\u003C/strong>, enabling both incremental improvements and fully optimized next-generation manufacturing strategies — supported by PlasmidFactory’s DNA manufacturing and \u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/news-and-stories/gmp-manufacturing-for-plasmid-and-minicircle-dna/\" tt-mode=\"url\">GMP expertise\u003C/a>.\u003C/p>",[141],{"url":142,"alt":143},"https://api.plasmidfactory.com/storage/257/responsive-images/_NBR0125_reduced_size___webp_W___WIDTH____H.webp",{"de":7,"en":144},"GMP Manufacturing at PlasmidFactory",[],{"headline":147,"subline":149,"description":150,"text":151,"images":153,"files":158},{"de":7,"en":148},"Why Partner with PlasmidFactory?",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":152},"\u003Cp>With more than 25 years of DNA manufacturing experience and \u003Cstrong>EU-based \u003C/strong>\u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/news-and-stories/gmp-manufacturing-for-plasmid-and-minicircle-dna/\" tt-mode=\"url\">\u003Cstrong>GMP capabilities\u003C/strong>\u003C/a>, PlasmidFactory supports AAV developers from early research to clinical production with:\u003C/p>\u003Cul>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>\u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/custom-dna/minicircle-dna/\" tt-mode=\"url\">Minicircle DNA technology\u003C/a>\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>\u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/news-and-stories/gmp-manufacturing-for-plasmid-and-minicircle-dna/\" tt-mode=\"url\">GMP-grade DNA manufacturing\u003C/a>\u003C/p>\u003C/li>\u003Cli>\u003Cp>\u003Cstrong>• \u003C/strong>Expertise in backbone-free vector design\u003C/p>\u003C/li>\u003C/ul>",[154],{"url":155,"alt":156},"https://api.plasmidfactory.com/storage/258/responsive-images/_NBR9768_reduced_size___webp_W___WIDTH____H.webp",{"de":7,"en":157},"Business Development Team",[],{"headline":160,"subline":162,"description":163,"text":164,"images":166,"files":167},{"de":7,"en":161},"Learn More",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":165},"\u003Cp>Explore how Minicircle DNA can strengthen vector quality, safety, and manufacturing robustness in your AAV program.\u003C/p>\u003Cp>Contact us at \u003Ca target=\"_blank\" href=\"mailto:contact@plasmidfactory.com\" tt-mode=\"url\">\u003Cstrong>contact@plasmidfactory.com\u003C/strong>\u003C/a>\u003C/p>",[],[],{"type":5,"title":169,"slug":171,"place":173,"description":174,"date":175,"links":176,"claim":181,"content":182},{"de":7,"en":170},"GMP Manufacturing for Plasmid & Minicircle DNA",{"de":7,"en":172},"gmp-manufacturing-for-plasmid-and-minicircle-dna",{"de":7,"en":7},{"de":170,"en":170},"2025-11-16",[177],{"title":178,"target":180},{"de":7,"en":179},"Video - GMP Manufacturing at PlasmidFactory","https://youtu.be/So3zMm3xgAs",{"de":7,"en":7},[183],{"headline":184,"subline":186,"description":187,"text":188,"images":190,"files":198},{"de":7,"en":185},"Meeting the highest standards for DNA products in advanced therapies!",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":189},"\u003Cp>At PlasmidFactory, the success of our customers has been our mission for over 25 years. As trusted CDMO for plasmid and Minicircle DNA, we also offer full GMP manufacturing capabilities designed to meet the demands of next-generation cell therapies, gene therapies, mRNA therapeutics, and vaccine development in clinical trials and commercial use.\u003C/p>\u003Cp>Our state-of-the-art GMP facility is purpose-built for the reliable, flexible, and scalable production of plasmid and Minicircle DNA. Equipped exclusively with qualified single-use technologies, advanced cleanroom environments, modern waste-management processes and stringent environmental controls, the facility ensures contamination-free manufacturing at the highest purity levels.\u003C/p>\u003Cp>All critical functions—from microbial cultivation to purification, aseptic filling, and in-house QC—are performed using fully validated processes and a robust quality management system. These measures guarantee consistent GMP-compliant DNA that meets the exacting regulatory requirements for clinical and commercial applications.\u003C/p>\u003Cp>With decades of experience, a unique focus on Minicircle DNA, and a strong track record of partnering with leading biotechnology and pharmaceutical companies, PlasmidFactory remains the reliable CDMO of choice for highest quality GMP DNA manufacturing.\u003C/p>",[191,195],{"url":192,"alt":193},"https://api.plasmidfactory.com/storage/240/responsive-images/BILD-GMP2024-web-%281%29___webp_W___WIDTH____H.webp",{"de":7,"en":194},"GMP Facility at PlasmidFactory",{"url":196,"alt":197},"https://api.plasmidfactory.com/storage/242/responsive-images/_NBR0125---Kopie___webp_W___WIDTH____H.webp",{"de":7,"en":144},[199],{"file":200,"title":201},"https://api.plasmidfactory.com/storage/245/Flyer-GMP-Grade-1125-2stg.pdf",{"de":7,"en":202},"GMP Manufacturing - Info Flyer",{"type":5,"title":204,"slug":206,"place":208,"description":209,"date":210,"links":211,"claim":212,"content":213},{"de":7,"en":205},"PlasmidFactory - The Minicircle Company - Info Sheet",{"de":7,"en":207},"plasmidfactory-the-minicircle-company-info-sheet",{"de":7,"en":7},{"de":205,"en":205},"2025-10-15",[],{"de":7,"en":7},[214],{"headline":215,"subline":216,"description":217,"text":218,"images":220,"files":224},{"de":7,"en":205},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":219},"\u003Cp>Download our company info sheet to learn how PlasmidFactory and its proprietary Minicircle DNA technology can enhance next-generation gene and cell therapy workflows.\u003C/p>",[221],{"url":222,"alt":223},"https://api.plasmidfactory.com/storage/209/responsive-images/CDMO-MC-Info-Sheet-Bild-Website___webp_W___WIDTH____H.webp",{"de":7,"en":205},[225],{"file":226,"title":227},"https://api.plasmidfactory.com/storage/210/Flyer-CDMO_MC_2-stg.-A4-final.pdf",{"de":7,"en":205},{"type":5,"title":229,"slug":231,"place":233,"description":234,"date":210,"links":235,"claim":236,"content":237},{"de":7,"en":230},"Improving AAV Production with Minicircles - Poster Presentation",{"de":7,"en":232},"improving-aav-production-with-minicircles-poster-presentation",{"de":7,"en":7},{"de":230,"en":230},[],{"de":7,"en":7},[238],{"headline":239,"subline":240,"description":241,"text":242,"images":244,"files":247},{"de":7,"en":230},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":243},"\u003Cp>Download our \u003Cstrong>\u003Cem>Improving AAV Production with Minicircles - Poster Presentation\u003C/em>\u003C/strong> to learn how Minicircle DNA technology can enhance AAV workflows.\u003C/p>",[245],{"url":7,"alt":246},{"de":7,"en":7},[248],{"file":249,"title":250},"https://api.plasmidfactory.com/storage/264/AAV-Poster-Presentation.pdf",{"de":7,"en":230},{"type":5,"title":252,"slug":254,"place":256,"description":257,"date":210,"links":258,"claim":259,"content":260},{"de":7,"en":253},"Minicircle Technology - Info Sheet",{"de":7,"en":255},"minicircle-technology-info-sheet",{"de":7,"en":7},{"de":253,"en":253},[],{"de":7,"en":7},[261],{"headline":262,"subline":263,"description":264,"text":265,"images":267,"files":270},{"de":7,"en":253},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":266},"\u003Cp>Download our Minicircle info sheet to learn how Minicircle DNA technology can enhance next-generation gene and cell therapy workflows.\u003C/p>",[268],{"url":7,"alt":269},{"de":7,"en":253},[271],{"file":272,"title":273},"https://api.plasmidfactory.com/storage/262/Minicircle-Overview---Flyer.pdf",{"de":7,"en":253},{"type":5,"title":275,"slug":277,"place":279,"description":280,"date":282,"links":283,"claim":284,"content":285},{"de":7,"en":276},"Minicircle DNA in AAV Production - Info Sheet",{"de":7,"en":278},"minicircle-dna-in-aav-production-info-sheet",{"de":7,"en":7},{"de":281,"en":281},"Minicircle DNA in AAV - Info Sheet","2025-10-14",[],{"de":7,"en":7},[286],{"headline":287,"subline":288,"description":289,"text":290,"images":292,"files":297},{"de":7,"en":276},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":291},"\u003Cp>Download our info sheet to learn how Minicircle DNA technology can enhance AAV production and improve gene therapy workflows.\u003C/p>",[293],{"url":294,"alt":295},"https://api.plasmidfactory.com/storage/205/responsive-images/AAV-Flyer-Product-Bild-Website___webp_W___WIDTH____H.webp",{"de":7,"en":296},"Info Sheet \"Minicircle DNA in AAV Production\"",[298],{"file":299,"title":300},"https://api.plasmidfactory.com/storage/206/Flyer-AAV_MC_2-stg.-A4-final.pdf",{"de":7,"en":276},{"type":5,"title":302,"slug":304,"place":306,"description":307,"date":282,"links":309,"claim":310,"content":311},{"de":7,"en":303},"Minicircle DNA in CAR-T Production - Info Sheet",{"de":7,"en":305},"minicircle-dna-in-car-t-production-info-sheet",{"de":7,"en":7},{"de":308,"en":303},"Minicircle DNA in CAR-T Production - Flyer",[],{"de":7,"en":7},[312],{"headline":313,"subline":314,"description":315,"text":316,"images":318,"files":323},{"de":7,"en":303},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":317},"\u003Cp>Download our info sheet to learn how Minicircle DNA technology can enhance CAR-T production and improve cell therapy workflows.\u003C/p>",[319],{"url":320,"alt":321},"https://api.plasmidfactory.com/storage/207/responsive-images/CAR-T-Flyer-Product-Bild-Website___webp_W___WIDTH____H.webp",{"de":7,"en":322},"Info Sheet \"Minicircle DNA in CAR-T Production\"",[324],{"file":325,"title":326},"https://api.plasmidfactory.com/storage/208/Flyer-CAR-T_MC_2-stg.-A4-final.pdf",{"de":7,"en":303},{"type":56,"title":328,"slug":331,"place":334,"description":336,"date":337,"links":338,"claim":343,"content":344},{"de":329,"en":330},"Press Release-Cooperation PlasmidFactory and Fraunhofer IZI","Press Release – Cooperation PlasmidFactory and Fraunhofer IZI",{"de":332,"en":333},"press release-cooperation-plasmidfactory-and-fraunhofer-izi","press-release-cooperation-plasmidfactory-and-fraunhofer-izi",{"de":7,"en":335},"Bielefeld/Leipzig",{"de":329,"en":329},"2025-10-08",[339],{"title":340,"target":342},{"de":7,"en":341},"More about Fraunhofer IZI","https://www.izi.fraunhofer.de/de/abteilungen/standort-wuerzburg/aussenstelle-zellulaere-immuntherapie",{"de":7,"en":7},[345],{"headline":346,"subline":348,"description":349,"text":350,"images":352,"files":361},{"de":7,"en":347},"PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":351},"\u003Cp>\u003Cstrong>Bielefeld/Leipzig, September 24, 2025 – PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients.\u003C/strong>\u003C/p>\u003Cp>PlasmidFactory GmbH, a leading European CDMO for plasmid and Minicircle DNA, brings more than 25 years of experience and over 3,500 DNA constructs delivered worldwide. The Fraunhofer IZI contributes extensive translational capabilities in immuno-oncology, regenerative medicine, and advanced cell manufacturing.\u003Cbr>Together, they are accelerating the development of next-generation, virus-free genetic engineering platforms while maintaining the highest quality and regulatory standards.\u003C/p>\u003Cp>In the past, the two partners have already successfully established new manufacturing processes for CAR-T cells at Fraunhofer IZI and conducted joint research projects on virus-free gene transfer, which served as the foundation for the production of clinical cell products.\u003C/p>\u003Cp>“By building on our long-standing collaboration, this partnership allows us to translate scientific innovation into tangible therapeutic advances,” says \u003Cstrong>Dr. Dirk Winnemöller, \u003C/strong>CEO of PlasmidFactory. “Together, we can streamline non-viral manufacturing workflows and bring promising therapies to patients more efficiently.”\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cstrong>Prof. Dr. Michael Hudecek\u003C/strong>, Fraunhofer IZI, adds: “PlasmidFactory’s expertise in high-quality DNA manufacturing perfectly complements our translational capabilities. By joining forces, we can further advance non-viral engineering platforms and help shape the future of cell and gene therapies.”\u003C/p>\u003Cp>Viral vectors remain the standard in many therapies, but they are associated with high costs, complex production, and safety concerns such as insertional mutagenesis. Minicircle DNA overcomes the limitations of conventional plasmids with higher transfection efficiency, stronger and more stable expression, and lower DNA toxicity – making it a real alternative to viral vectors and a key enabler of virus-free engineering approaches for CAR-T, TCR-T, NK, and other immune cell therapies.\u003Cbr>\u003C/p>\u003Cp>The collaboration underscores a shared commitment to advancing virus-free technologies such as minicircles and transposon systems, which have the potential to overcome bottlenecks in viral vector production. By aligning innovation with patient needs, PlasmidFactory and Fraunhofer IZI are creating a platform that strengthens Europe’s position in the global race for advanced therapies.\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cstrong>About Fraunhofer IZI\u003C/strong>\u003Cbr>The Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig conducts applied research and development in immuno-oncology, cell and gene therapy, and biomanufacturing. The institute develops innovative solutions from basic research to clinical application in close collaboration with partners from academia and industry.\u003C/p>\u003Cp> \u003C/p>\u003Cp>\u003Cstrong>About PlasmidFactory GmbH\u003C/strong>\u003Cbr>PlasmidFactory GmbH, based in Bielefeld, Germany, is a leading global manufacturer of high-quality plasmids and Minicircles. Its products are used in research, preclinical, and clinical projects, covering applications from basic research to the development of advanced cell and gene therapies. With a focus on quality and customer benefit, PlasmidFactory has supported international partners from science and industry since 2000.\u003C/p>",[353,357],{"url":354,"alt":355},"https://api.plasmidfactory.com/storage/201/responsive-images/izi_60mm_CMYK-Kopie___webp_W___WIDTH____H.webp",{"de":7,"en":356},"Fraunhofer IZI",{"url":358,"alt":359},"https://api.plasmidfactory.com/storage/202/responsive-images/PF-Logo-2025-1620x1620-weiss___webp_W___WIDTH____H.webp",{"de":7,"en":360},"PlasmidFactory",[362,366],{"file":363,"title":364},"https://api.plasmidfactory.com/storage/203/PressRelease-Cooperation-PlasmidFactory-and-Fraunhofer-IZI-10.2025-EN.pdf",{"de":7,"en":365},"PressRelease-Cooperation PlasmidFactory and Fraunhofer IZI",{"file":367,"title":368},"https://api.plasmidfactory.com/storage/204/PressRelease-Zusammenarbeit-PlasmidFactory-und-Fraunhofer-IZI-10.2025-DE.pdf",{"de":7,"en":369},"PressRelease-Zusammenarbeit PlasmidFactory und Fraunhofer IZI",{"type":56,"title":371,"slug":374,"place":376,"description":378,"date":381,"links":382,"claim":387,"content":388},{"de":372,"en":373},"Presse Information Innovationspreis NRW 2025 für Dr. Martin Schleef","Press Release – Innovation Award NRW 2025 for Dr. Martin Schleef",{"de":375,"en":375},"press-release",{"de":7,"en":377},"Düsseldorf/Bielefeld",{"de":379,"en":380},"PlasmidFactory-Gründer Dr. Martin Schleef mit Innovationspreis NRW 2025 ausgezeichnet","PlasmidFactory founder Dr Martin Schleef awarded the NRW Innovation Prize 2025","2025-09-08",[383],{"title":384,"target":386},{"de":7,"en":385},"Innovationspreisträger NRW 2025","https://www.wirtschaft.nrw/innovationspreis-nrw-2025-nordrhein-westfalen-entsteht-zukunft",{"de":7,"en":7},[389],{"headline":390,"subline":392,"description":393,"text":394,"images":397,"files":406},{"de":379,"en":391},"PlasmidFactory founder Dr. Martin Schleef honored with the NRW Innovation Award 2025",{"de":7,"en":7},{"de":7,"en":7},{"de":395,"en":396},"\u003Cp>\u003Cstrong>\u003Cspan>Düsseldorf/Bielefeld, 8. September 2025 – Der Gründer und langjährige Geschäftsführer der PlasmidFactory GmbH, Dr. Martin Schleef, wurde heute in Düsseldorf mit dem Innovationspreis des Landes Nordrhein-Westfalen 2025 geehrt.\u003C/span>\u003C/strong>\u003C/p>\u003Cp>\u003Cspan>Der Innovationspreis gehört zu den bedeutendsten Auszeichnungen Deutschlands und wird jährlich vom Ministerium für Wirtschaft, Industrie, Klimaschutz und Energie des Landes NRW vergeben. Mit ihm werden Persönlichkeiten ausgezeichnet, die durch herausragende Forschungs- und Transferleistungen Wirtschaft, Wissenschaft und Gesellschaft nachhaltig geprägt haben.\u003C/span>\u003C/p>\u003Cp>\u003Cem>\u003Cspan>„Diese Auszeichnung ist für mich eine große Ehre und zugleich eine Würdigung der Arbeit, die wir gemeinsam bei PlasmidFactory über viele Jahre geleistet haben. Innovation war von Anfang an unser Antrieb – insbesondere die Entwicklung von fortschrittlichen DNA-Lösungen wie dem Minicircle, die entscheidend dazu beigetragen haben, das Feld der Zell- und Gentherapie voranzubringen. Umso mehr freue ich mich, dass dieser Weg nun auf so eindrucksvolle Weise Anerkennung findet“,\u003C/span>\u003C/em>\u003Cspan> sagt\u003C/span>\u003Cstrong>\u003Cspan> Dr. Martin Schleef\u003C/span>\u003C/strong>\u003Cspan>, Gründer und CEO der letzten 25 Jahre von PlasmidFactory.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>Die PlasmidFactory wurde im Jahr 2000 in Bielefeld gegründet. Unter der Führung von Dr. Schleef entwickelte sich das Unternehmen von einem Spin-off zu einem international führenden Anbieter für hochqualitative DNA-Produkte. Heute liefert PlasmidFactory Plasmide und Minicircles u.a. zur Herstellung von Adeno-assoziierte Vektoren (AAV), mRNA und Zelltherapien bis hin zur GMP-Qualität an akademische Einrichtungen, Biotech- und Pharmaunternehmen weltweit. Mit diesen Produkten unterstützt das Unternehmen entscheidend die Forschung und klinische Entwicklung in den Bereichen Gen- und Zelltherapie, sowie Impfstoffentwicklung.\u003C/span>\u003C/p>\u003Cp>\u003Cem>\u003Cspan>„Wir sind stolz, diese Erfolgsgeschichte fortzuführen. Der Innovationspreis NRW ist nicht nur eine Auszeichnung für die Leistungen von Dr. Schleef, sondern auch ein Ansporn für uns alle, die Zukunft der Biotechnologie und insbesondere der Zell- und Gentherapie weiter aktiv mitzugestalten. Seine Pionierarbeit ist die Basis, auf der wir heute mit unserem Team aufbauen – und die wir mit unseren hochwertigen DNA-Lösungen konsequent weiterentwickeln“\u003C/span>\u003C/em>\u003Cspan>,\u003C/span>\u003Cstrong>\u003Cspan> \u003C/span>\u003C/strong>\u003Cspan>betont\u003C/span>\u003Cstrong>\u003Cspan> Dr. Dirk Winnemöller\u003C/span>\u003C/strong>\u003Cspan>, CEO von PlasmidFactory.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>Mit 25 Jahren Erfahrung, einem internationalen Kundenstamm und modernsten Produktionsanlagen ist PlasmidFactory heute ein wichtiger Partner für die Entwicklung und Herstellung neuartiger Therapien.\u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan> \u003C/span>\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>Über den Innovationspreis NRW\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>Der Innovationspreis des Landes Nordrhein-Westfalen wird seit 2008 vergeben und zählt zu den höchstdotierten Innovationspreisen in Deutschland. Er würdigt herausragende Leistungen in den Kategorien „innovation“, „innovation2business“, „innovation2market“ und „innovation4transformation“ und trägt dazu bei, die Innovationskraft des Landes sichtbar zu machen.\u003C/span>\u003C/p>\u003Cp>\u003Cspan> \u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>Über PlasmidFactory\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>Die PlasmidFactory GmbH mit Sitz in Bielefeld ist ein weltweit führender Hersteller von hochqualitativen Plasmiden und Minicircles. Die Produkte werden in Forschungs-, präklinischen und klinischen Projekten eingesetzt und decken Anwendungen von der Grundlagenforschung bis zur Entwicklung innovativer Gen- und Zelltherapien\u003C/span>\u003Cstrong>\u003Cspan> \u003C/span>\u003C/strong>\u003Cspan>ab. Mit einem klaren Fokus auf Qualität und Kundennutzen unterstützt PlasmidFactory seit 2000 internationale Partner aus Wissenschaft und Industrie bei der Umsetzung ihrer biotechnologischen Innovationen.\u003C/span>\u003C/p>\u003Cp>\u003Cspan> \u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>\u003Cu>Kontakt:\u003C/u>\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>Dr. Marcello Stein (Senior Director Marketing)\u003Cbr>PlasmidFactory GmbH \u003Cbr>Meisenstraße 96\u003Cbr>33607 Bielefeld, Germany\u003Cbr>+49 521 2997 \u003C/span>\u003Ca target=\"_blank\" href=\"mailto:350presse@plasmidfactory.com\" tt-mode=\"url\">\u003Cspan>350\u003Cbr>presse@plasmidfactory.com\u003C/span>\u003C/a>\u003Cspan>\u003Cbr>\u003Cbr>\u003C/span>\u003Ca target=\"_blank\" href=\"http://www.plasmidfactory.com\" tt-mode=\"url\">\u003Cspan>www.plasmidfactory.com\u003C/span>\u003C/a>\u003C/p>","\u003Cp>\u003Cstrong>\u003Cspan>Düsseldorf/Bielefeld, September 8, 2025 – The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored today in Düsseldorf with the Innovation Award 2025 of the State of North Rhine-Westphalia.\u003C/span>\u003C/strong>\u003C/p>\u003Cp>\u003Cspan>The award is one of Germany's most prestigious innovation awards and is presented annually by the Ministry of Economic Affairs, Industry, Climate Protection, and Energy of the State of North Rhine-Westphalia. It honors individuals who have made a lasting impact on business, science, and society through outstanding research and transfer achievements.\u003C/span>\u003C/p>\u003Cp>\u003Cem>\u003Cspan>\"This award is a great honor for me and at the same time a recognition of the work we have done together at PlasmidFactory over many years. Innovation has been our driving force from the very beginning—in particular, the development of advanced DNA solutions such as Minicircle, which have made a decisive contribution to advancing the field of cell and gene therapy. I am therefore all the more delighted that this approach is now receiving such impressive recognition,\" \u003C/span>\u003C/em>\u003Cspan>says \u003C/span>\u003Cstrong>\u003Cspan>Dr. Martin Schleef,\u003C/span>\u003C/strong>\u003Cspan> founder and CEO of PlasmidFactory for the last 25 years.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>PlasmidFactory was founded in Bielefeld in 2000. Under the leadership of Dr. Schleef, the company developed from a spin-off into a leading international supplier of high-quality DNA products. Today, PlasmidFactory supplies plasmids and minicircles for the production of adeno-associated vectors (AAV), mRNA, and cell therapies, among other things, up to GMP quality to academic institutions, biotech, and pharmaceutical companies worldwide. With these products, the company provides crucial support for research and clinical development in the fields of gene and cell therapy, as well as vaccine development.\u003C/span>\u003C/p>\u003Cp>\u003Cem>\u003Cspan>\"We are proud to continue this success story. The NRW Innovation Award is not only a recognition of Dr. Schleef's achievements, but also an incentive for all of us to continue actively shaping the future of biotechnology, and cell and gene therapy in particular. His pioneering work is the foundation on which we are building today with our team – and which we are consistently developing further with our high-quality DNA solutions,\" \u003C/span>\u003C/em>\u003Cspan>emphasizes \u003C/span>\u003Cstrong>\u003Cspan>Dr. Dirk Winnemöller,\u003C/span>\u003C/strong>\u003Cspan> CEO of PlasmidFactory.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>With 25 years of experience, an international customer base, and state-of-the-art production facilities, PlasmidFactory is now an important partner for the development and manufacture of novel therapies.\u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>\u003Cbr>About the NRW Innovation Award\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>The Innovation Award of the State of North Rhine-Westphalia has been presented since 2008 and is one of the most highly endowed innovation awards in Germany. It recognizes outstanding achievements in the categories “innovation,” “innovation2business,” “innovation2market,” and “innovation4transformation” and helps to highlight the state's innovative strength.\u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>About PlasmidFactory\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>PlasmidFactory GmbH, based in Bielefeld, Germany, is a leading global manufacturer of high-quality plasmids and minicircles. Its products are used in research, preclinical, and clinical projects, covering applications ranging from basic research to the development of innovative gene and cell therapies. With a clear focus on quality and customer benefit, PlasmidFactory has been supporting international partners from science and industry in implementing their biotechnological innovations since 2000.\u003C/span>\u003C/p>\u003Cp>\u003Cspan> \u003C/span>\u003C/p>\u003Cp>\u003Cstrong>\u003Cspan>\u003Cu>Contact:\u003C/u>\u003Cbr>\u003C/span>\u003C/strong>\u003Cspan>Dr. Marcello Stein (Senior Director Marketing)\u003Cbr>PlasmidFactory GmbH \u003Cbr>Meisenstraße 96\u003Cbr>33607 Bielefeld, Germany\u003Cbr>+49 521 2997 \u003C/span>\u003Ca target=\"_blank\" href=\"mailto:350presse@plasmidfactory.com\" tt-mode=\"url\">\u003Cspan>350\u003Cbr>presse@plasmidfactory.com\u003C/span>\u003C/a>\u003Cspan>\u003Cbr>\u003Cbr>\u003C/span>\u003Ca target=\"_blank\" href=\"http://www.plasmidfactory.com\" tt-mode=\"url\">\u003Cspan>www.plasmidfactory.com\u003C/span>\u003C/a>\u003C/p>",[398,402],{"url":399,"alt":400},"https://api.plasmidfactory.com/storage/188/responsive-images/BILD-MartinSchleef1-2025___webp_W___WIDTH____H.webp",{"de":7,"en":401},"Dr. Martin Schleef",{"url":403,"alt":404},"https://api.plasmidfactory.com/storage/191/responsive-images/BILD-MartinSchleef2-2025___webp_W___WIDTH____H.webp",{"de":7,"en":405},"Dr. Martin Schleef mit dem Innovationspreis NRW 2025",[407,412],{"file":408,"title":409},"https://api.plasmidfactory.com/storage/196/Press-Information-InnovationAward-NRW-2025-EN.pdf",{"de":410,"en":411},"Presse Information EN","Press Information EN",{"file":413,"title":414},"https://api.plasmidfactory.com/storage/194/PresseInformation-Innovationspreis-NRW-2025-DE.pdf",{"de":415,"en":415},"Presse Information DE",{"type":56,"title":417,"slug":419,"place":421,"description":422,"date":424,"links":425,"claim":426,"content":427},{"de":7,"en":418},"Subscribe & Save 5%",{"de":7,"en":420},"subcribe-save-5",{"de":7,"en":7},{"de":423,"en":423},"Are you working in gene therapy, cell therapy or vaccine development? Stay informed with the latest insights from PlasmidFactory. Get discount!","2025-02-27",[],{"de":7,"en":7},[428],{"headline":429,"subline":431,"description":432,"text":433,"images":435,"files":440},{"de":7,"en":430},"Stay ahead in the World of Minicircles & Plasmid DNA with our Newsletter",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":434},"\u003Cp>Are you working in gene therapy, cell therapy or vaccine development? Stay informed with the latest insights from PlasmidFactory. \u003C/p>\u003Cp>\u003Cstrong>Get the promo code for your next order*\u003C/strong>\u003C/p>\u003Cp>\u003Cstrong>Why subscribe to our newsletter?\u003C/strong>\u003Cbr>-\u003Cstrong> Exclusive updates on plasmid and minicircle DNA research\u003C/strong>\u003Cbr>-\u003Cstrong> Biotech industry trends, case studies, and expert perspectives\u003C/strong>\u003Cbr>-\u003Cstrong> Early access to promotions and events\u003C/strong>\u003C/p>\u003Cp>Stay informed. Stay innovative. Subscribe today: \u003Cbr>\u003Ca target=\"_blank\" href=\"https://www.plasmidfactory.com/newsletter-subscription/\" tt-mode=\"url\">Newsletter Subscription\u003C/a>\u003C/p>\u003Cp>\u003Cem>* Register now via our homepage and enjoy a one-time 5% discount on your next order this year – applicable for Research grade and CCC grade material. This discount cannot be combined with other discounts.\u003C/em>\u003C/p>",[436],{"url":437,"alt":438},"https://api.plasmidfactory.com/storage/167/responsive-images/BILD-5Prozent-NL-Rabatt-web___webp_W___WIDTH____H.webp",{"de":7,"en":439},"Subscribe and save 5% with selected plasmid products",[],{"type":56,"title":442,"slug":444,"place":446,"description":448,"date":450,"links":451,"claim":456,"content":457},{"de":7,"en":443},"Partnership with Rane Rao Reshamia Laboratories in India",{"de":7,"en":445},"partnership-with-rane-rao-reshamia-laboratories-in-india",{"de":7,"en":447},"Bielefeld/Germany",{"de":449,"en":443},"Partnerschaft mit Rane Rao Reshamia Laboratories in Indien","2024-07-04",[452],{"title":453,"target":455},{"de":7,"en":454},"Visit RRR Labs ","https://www.rrrlabs.com",{"de":7,"en":7},[458],{"headline":459,"subline":461,"description":462,"text":463,"images":465,"files":469},{"de":7,"en":460},"Dr. Nagaraj Rao – our new agent in India",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":464},"\u003Cp>\u003Cspan>We are delighted to announce our newly forged partnership with Rane Rao Reshamia Laboratories (RRR). This collaboration will enhance our market reach and streamline distribution, making our plasmids and minicircles more accessible to customers in India.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>We look forward to the mutual growth and success this partnership will bring. Thank you to everyone involved in making this possible.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>About RRR:\u003C/span>\u003C/p>\u003Cp>\u003Cspan>RRR is located in Navi Mumbai, India and is engaged in business activities related to manufacturing and services in fine chemicals, pharmaceuticals, biotechnology, surface coatings technology and platinum group metals. RRR has been working closely with its partners, mainly in Europe and the USA, for many years.\u003C/span>\u003C/p>\u003Cp>\u003Cspan>Visit RRR Labs (\u003C/span>\u003Ca target=\"_blank\" href=\"https://www.rrrlabs.com/\" tt-mode=\"url\">\u003Cspan>https://www.rrrlabs.com/\u003C/span>\u003C/a>\u003Cspan>) for more information and contact details.\u003C/span>\u003C/p>",[466],{"url":467,"alt":468},"https://api.plasmidfactory.com/storage/118/responsive-images/Dr.-Nagaraj-Rao-web___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":56,"title":471,"slug":473,"place":475,"description":476,"date":479,"links":480,"claim":481,"content":482},{"de":7,"en":472},"Publication in “Molecular Biology”",{"de":7,"en":474},"publication-in-methods-in-molecular-biology",{"de":7,"en":447},{"de":477,"en":478},"PlasmidFactory gibt Einblicke in die Herstellung hochwertiger Plasmid-DNA als Vorlage für die Produktion von mRNA-Impfstoffen","Publication in “Molecular Biology”: PlasmidFactory shares insights on producing high-quality plasmid DNA as template for production of mRNA vaccines","2024-06-26",[],{"de":7,"en":7},[483],{"headline":484,"subline":485,"description":486,"text":487,"images":489,"files":493},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":488},"\u003Cp>\u003Cstrong>Exciting developments in plasmid DNA manufacturing from PlasmidFactory!\u003C/strong>\u003C/p>\u003Cp>Ram Shankar, Marco Schmeer, and Martin Schleef of PlasmidFactory share insights on producing high-quality plasmid DNA as template for production of mRNA vaccines in a just published \"Methods in Molecular Biology“ book chapter\u003C/p>\u003Cp>Key takeaways:\u003C/p>\u003Cp>• PlasmidFactory's \"High-Quality\" grade meets regulatory requirements \u003Cbr>• The proprietary chromatography purification achieves high purity and homogeneity\u003Cbr>• PlasmidFactory scaled up processes to yield multiple grams in short time\u003Cbr>• Rigorous quality controls ensure suitability for clinical applications\u003C/p>\u003Cp>PlasmidFactory's expertise in plasmid DNA production is crucial as mRNA vaccines gain prominence. We are proud to see PlasmidFactory leading the way in meeting global demand!\u003Cbr>If you are interested in this topic, please contact us. \u003C/p>",[490],{"url":491,"alt":492},"https://api.plasmidfactory.com/storage/127/responsive-images/RNA-Vaccines-Buch-web___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":5,"title":495,"slug":498,"place":501,"description":502,"date":505,"links":506,"claim":507,"content":508},{"de":496,"en":497},"Plasmid & Minicircle DNA – Product-Overview 4-2024","Plasmid & Minicircle DNA – Product-Overview",{"de":499,"en":500},"plasmid-minicircle-dna-product-overview-4-2024","plasmid-minicircle-dna-product-overview",{"de":7,"en":7},{"de":503,"en":504},"Plasmid & Minicircle DNA - Produkt-Übersicht: unsere aktuelle Produktübersicht mit verschiedenen Qualitätsstufen für Ihre spezifischen Anforderungen.","Plasmid & Minicircle DNA - Product overview: our current product overview with different quality levels for your specific requirements.","2024-04-21",[],{"de":7,"en":7},[509],{"headline":510,"subline":512,"description":513,"text":514,"images":516,"files":520},{"de":7,"en":511},"Plasmid & Minicircle Products",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":515},"\u003Cp>Download our current product overview here with various qualitates grades to suit your specific requirements!\u003C/p>",[517],{"url":518,"alt":519},"https://api.plasmidfactory.com/storage/163/responsive-images/BILD-Produktfolder___webp_W___WIDTH____H.webp",{"de":7,"en":7},[521],{"file":522,"title":523},"https://api.plasmidfactory.com/storage/185/Produkt-Folder-V11-2025-final.pdf",{"de":7,"en":511},{"type":56,"title":525,"slug":528,"place":531,"description":532,"date":535,"links":536,"claim":537,"content":539},{"de":526,"en":527},"Endless space – Neue Lagerhalle","Endless space – New Storage Building",{"de":529,"en":530},"endless-space-neue-lagerhalle","endless-space-new-storage-building",{"de":7,"en":447},{"de":533,"en":534},"Platz ohne Ende - Neues Lagergebäude: zusätzliche 240 Quadratmeter Fläche für moderne Lagerhaltung","Endless space – New Storage Building: additional 240 square metres of space for modern storage","2024-02-02",[],{"de":7,"en":538},"How much space do we want? More. Do we have it? Yes, finally!",[540],{"headline":541,"subline":543,"description":544,"text":545,"images":547,"files":554},{"de":7,"en":542},"More space at last! ",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":546},"\u003Cp>From now on we have an additional 240 square metres of space for modern storage. The new storage building has been filled and is now professionally managed and organised: We keep an eye on warehouse and logistics processes and constantly optimise control over warehouse activities and the availability of materials.\u003C/p>",[548,551],{"url":549,"alt":550},"https://api.plasmidfactory.com/storage/111/responsive-images/Rohbau___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":552,"alt":553},"https://api.plasmidfactory.com/storage/112/responsive-images/MoreSpace___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":5,"title":556,"slug":558,"place":560,"description":561,"date":564,"links":565,"claim":566,"content":567},{"de":7,"en":557},"Modern GMP-compliant facility",{"de":7,"en":559},"modern-gmp-compliant-facility",{"de":7,"en":447},{"de":562,"en":563},"Moderne GMP-konforme Anlage für Plasmide und insbesondere für Minicircle-DNA in großen Mengen weltweit","Modern GMP-compliant facility for plasmids and, in particular, for minicircle DNA in large quantities worldwide","2024-01-01",[],{"de":7,"en":7},[568],{"headline":569,"subline":571,"description":572,"text":573,"images":575,"files":579},{"de":7,"en":570},"Our passion is the success of our customers.",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":574},"\u003Cp>As a reliable partner, we will therefore soon be offering the highest quality level - GMP quality - in addition to the previously available application-related quality levels for minicircles and plasmids (Research, CCC, HQ). After completion of our GMP facility, which is currently under construction, we will be able to fulfil all our customers' requirements from research via clinical examination to market supply.  \u003C/p>\u003Cp>To this end, our GMP-compliant facility will be equipped with the latest technologies, from airlock systems to media quality and clean room environments. We have placed the utmost importance on ensuring that the process equipment prevents cross-contamination. The high requirements are also consistently implemented in our quality control, with qualified devices and validated methods. All relevant areas, procedures and processes are embedded in a reliable GMP quality management system. This enables us to deliver the optimum quality for every customer.\u003C/p>",[576],{"url":577,"alt":578},"https://api.plasmidfactory.com/storage/164/responsive-images/BILD-GMP2025-web___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":5,"title":581,"slug":584,"place":586,"description":589,"date":592,"links":593,"claim":594,"content":596},{"de":582,"en":583},"ESGCT '23 Lunchtime Symposium","ESGCT, 2023 Lunchtime Symposium",{"de":585,"en":585},"esgct-23-lunch-symposium-minicircles-next-generation-gene-vectors-with-high-potential-for-clinical-applications",{"de":587,"en":588},"Rom","Brussels/Belgium",{"de":590,"en":591},"Thema des Symposiums auf der ESGCT 2023: Minicircles - Genvektoren der nächsten Generation mit hohem Potenzial für klinische Anwendungen","Topic of the symposium at the ESGCT 2023: Minicircles – next-generation gene vectors with high potential for clinical applications","2023-10-26",[],{"de":7,"en":595},"The absence of undesired backbone sequences removes the possibility of these sequences being falsely packaged into the transfer vectors.",[597],{"headline":598,"subline":601,"description":602,"text":603,"images":606,"files":613},{"de":599,"en":600},"Join our ESGCT Lunchtime Symposium OCT 26","Minicircles: next-generation gene vectors with high potential for clinical applications",{"de":7,"en":7},{"de":7,"en":7},{"de":604,"en":605},"\u003Cp>\u003Cstrong>Why is PlasmidFactory’s minicircle so awesome?\u003C/strong>\u003Cbr>Get more answers at the ESGCT in Brussels from our invited speakers experienced in the application:\u003C/p>\u003Cp>\u003Cstrong>Univ. -Prof. Dr. med. Michael Hudecek\u003C/strong>, University Hospital, Würzburg, Germany\u003Cbr>Advanced strategies for gene transfer and gene editing in CAR-T cells\u003C/p>\u003Cp>\u003Cstrong>Dr. Kathrin Teschner\u003C/strong>, Sartorius Xell GmbH, Schloss Holte-Stukenbrock, Germany\u003Cbr>Use of minicircles for the production of AAV in HEK293 cells\u003C/p>\u003Cp>\u003Cstrong>Dr. Thijs Gerritzen\u003C/strong>, Amarna Therapeutics, Leiden, The Netherlands.\u003Cbr>Generation of a new, re-dosable, SV40 viral vector based on minicircle DNA\u003C/p>\u003Cp>\u003Cstrong>Chairs:\u003C/strong>\u003Cbr>Dr. Daniel Scherman, Université Paris Descartes, Paris, France\u003Cbr>Dr. Martin Schleef, PlasmidFactory GmbH, Bielefeld, Germany\u003C/p>","\u003Cp>The promise of gene therapy in the clinic is dependent on the efficient delivery of the corresponding nucleic acids into target cells or tissues. The field has seen some major advances with both viral as well as non-viral vectors as delivery vehicles. Plasmid DNA containing the gene of interest continue to serve as essential starting material for both these strategies. In the past few years, regulatory development has resulted in the need for safe and advanced next generation delivery vehicles. Among many alternatives presented in the field, minicircles offer certain unique advantages and these would be focused upon during this symposium.\u003C/p>\u003Cp>Minicircles are plasmid derivatives engineered to be devoid of bacterial sequence elements such antibiotic resistance genes or replication origin. In this way, they represent a meaningful adaptation of the idea of a gene delivery vehicle – without the problematic and unnecessary sequence elements. Apart from the reduction in size compared to the original plasmid, the trimming away of excess sequence enables the molecule to better evade host immune responses ultimately being better poised to circumvent gene silencing scenarios post-transfection. Moreover, with the removal of the resistance genes, these constructs are a safe bet from a regulatory standpoint going forward to the next generation of gene therapies.\u003C/p>\u003Cp>Thanks to the reduction in size, for example, the amount of DNA required for nucleofecting T-cells can be reduced. Our collaborators used a non-viral sleeping beauty-based transposition to generate CAR-T cells whereby a higher transposition rate was noticed while using minicircles as compared to plasmids. The reduced DNA toxicity experienced by the cells contributed ultimately to a higher yield of CAR-modified T cells. These minicircles were produced in High Quality grade allowing for the GMP production of such CAR-T cells which have actually entered the clinic.\u003C/p>\u003Cp>When used for AAV production, minicircles offer certain unique advantages. The absence of undesired backbone sequences removes the possibility of these sequences being falsely packaged into the transfer vectors. In one of the studies by our collaborators, a head-to-head comparison with the use of plasmids revealed up to a four-fold increase in vector genome yield.\u003C/p>\u003Cp>Furthermore, minicircles are now being used to generate new and better viral vectors based on other systems which will also be showcased in this symposium.\u003C/p>\u003Cp>Finally, PlasmidFactory will touch upon certain unique aspects of these minicircles and elucidate where they stand among the different types of minimal expression cassettes. This would help to bring much needed clarity among gene therapy researchers in this fast-changing landscape.\u003C/p>\u003Cp>\u003Cstrong>Invited speakers:\u003C/strong>\u003Cbr>1.     Univ. -Prof. Dr. med. Michael Hudecek, University Hospital, Würzburg, Germany\u003Cbr>\u003Cem>Advanced strategies for gene transfer and gene editing in CAR-T cells\u003C/em>\u003C/p>\u003Cp>2.     Dr. Kathrin Teschner, Sartorius Xell GmbH, Schloss Holte-Stukenbrock, Germany\u003Cbr>\u003Cem>Use of minicircles for the production of AAV in HEK293 cells\u003C/em>\u003C/p>\u003Cp>3.     Dr. Thijs Gerritzen, Amarna Therapeutics, Leiden, The Netherlands.\u003Cbr>\u003Cem>Generation of a new, re-dosable, SV40 viral vector based on minicircle DN\u003C/em>\u003C/p>\u003Cp>\u003Cstrong>Chairs:\u003C/strong>\u003Cbr>1.     Dr. Daniel Scherman, Université Paris Descartes, Paris, France\u003Cbr>2.     Dr. Martin Schleef, PlasmidFactory GmbH, Bielefeld, Germany\u003C/p>",[607,610],{"url":608,"alt":609},"https://api.plasmidfactory.com/storage/89/responsive-images/LunchSymposium-Teller-Bild___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":611,"alt":612},"https://api.plasmidfactory.com/storage/90/responsive-images/Halle-mit-Publikum___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":56,"title":615,"slug":617,"place":619,"description":620,"date":623,"links":624,"claim":625,"content":627},{"de":616,"en":616},"Biotech Hall of Fame",{"de":618,"en":618},"biotech-hall-of-fame",{"de":7,"en":447},{"de":621,"en":622},"Erfolgsgeschichten der deutschen Biotechnologie: Biotech Hall of Fame","German biotechnology success stories: Biotech Hall of Fame","2023-05-31",[],{"de":7,"en":626},"PlasmidFactory - The lord of the rings",[628],{"headline":629,"subline":631,"description":632,"text":633,"images":635,"files":639},{"de":7,"en":630},"German biotechnology success stories",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":634},"\u003Cp>Martin Schleef is convinced that the global demand for plasmids will far exceed their supply in the coming years.\u003Cbr>\"Die PlasmidFactory ist so alt wie das Jahrhundert. Mit dessen bisher größten medizinischen Innovationen, den Gen- und Immuntherapien, wächst sie in eindrucksvollem Tempo heran. Aus ursprünglich vier Beschäftigten sind mittlerweile 34 geworden, der Umsatz hat sich in jedem der drei vergangenen Jahre verdoppelt. Besonders für mRNA-Impfstoffe und CAR-T-Zelltherapien werden die hochwertigen Plasmide und Plasmidderivate des Bielefelder Unternehmens in aller Welt immer stärker nachgefragt.\" (Dr. Claudia Englbrecht)\u003C/p>\u003Cp>\u003C/p>",[636],{"url":637,"alt":638},"https://api.plasmidfactory.com/storage/109/responsive-images/BIO-Deutschland___webp_W___WIDTH____H.webp",{"de":7,"en":7},[640],{"file":641,"title":642},"https://api.plasmidfactory.com/storage/110/2_Presse-Info-HallOfFame-BioDeutschland.pdf",{"de":7,"en":643},"More information in German",{"type":56,"title":645,"slug":647,"place":649,"description":651,"date":654,"links":655,"claim":660,"content":662},{"de":646,"en":646},"BioPharm International: Achieving High Yields in Upstream Processing of Plasmids",{"de":648,"en":648},"biopharm-international-achieving-high-yields-in-upstream-processing-of-plasmids",{"de":7,"en":650},"Germany",{"de":652,"en":653},"redaktioneller Artikel in BioPharm International: Achieving High Yields in Upstream Processing of Plasmids","editorial article in BioPharm International: Achieving High Yields in Upstream Processing of Plasmids","2023-03-23",[656],{"title":657,"target":659},{"de":7,"en":658},"BioPharm International","https://www.biopharminternational.com/view/achieving-high-yields-in-upstream-processing-of-plasmids",{"de":7,"en":661},"We have developed strategies that keep productivity high without having to rely on antibiotics while controlling for the maintenance of critical sequence structures in the product",[663],{"headline":664,"subline":666,"description":667,"text":668,"images":670,"files":674},{"de":7,"en":665},"We are pleased to have this cover story",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":669},"\u003Cp>In this study, the structural differences of the USP mAbs are characterized using Circular Dichroism (CD) and Infrared (IR) Spectroscopy across three instrument platforms in a multi-laboratory study. \u003Cbr>Published on: March 2, 2023\u003Cbr>Cynthia A. Challener\u003Cbr>BioPharm International, BioPharm International, March 2023, Volume 36, Issue 03\u003Cbr>Pages: 10–13, 36\u003Cbr>“We have developed strategies that keep productivity high without having to rely on antibiotics while controlling for the maintenance of critical sequence structures in the product (e.g., ITR sequences for productive adeno-associated virus [AAV] manufacturing or polyA tracks for mRNA manufacturing).” Dr Ram Shankar, Head of R&D PlasmidFactory GmbH\u003Cbr>\u003C/p>",[671],{"url":672,"alt":673},"https://api.plasmidfactory.com/storage/94/responsive-images/BioPharm___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":56,"title":676,"slug":679,"place":681,"description":683,"date":685,"links":686,"claim":687,"content":689},{"de":677,"en":678},"PlasmidFactory gibt die Ernennung von Berthold Hackl und Dr. Eduard Ayuso in den Beirat bekannt","Appointment of Berthold Hackl and Dr. Eduard Ayuso to Board of Directors",{"de":680,"en":680},"plasmidfactory-announces-appointment-of-berthold-hackl-and-dr-eduard-ayuso-to-board-of-directors",{"de":682,"en":447},"Bielefeld, Deutschland",{"de":684,"en":678},"Ernennung von Berthold Hackl und Dr. Eduard Ayuso zu Mitgliedern des Boards","2023-03-14",[],{"de":7,"en":688},"I have been always impressed by the quality and the scientific knowledge of the team; PlasmidFactory is a true industry pioneer in the field!",[690,709],{"headline":691,"subline":694,"description":695,"text":696,"images":699,"files":708},{"de":692,"en":693},"Der führende Auftragshersteller und Dienstleister für Plasmid- und Minicircle-DNA - PlasmidFactory - gibt heute die Ernennung der beiden Beiratsmitglieder Berthold Hackl und Dr. Eduard Ayuso zum Vorsitzenden bzw. zum Mitglied des Beirats bekannt. ","PlasmidFactory announces today the appointment of two board members, Berthold Hackl and Dr. Eduard Ayuso as chairman and member of the board, respectively. ",{"de":7,"en":7},{"de":7,"en":7},{"de":697,"en":698},"\u003Cp>Die beiden Branchenexperten treten in den Beirat der PlasmidFactory ein, um die strategische Entwicklung und Positionierung des Unternehmens weiter zu unterstützen; ihr umfangreiches industrielles und wissenschaftliches Know-how wird wesentlich zur Wachstumsbeschleunigung von PlasmidFactory beitragen.\u003C/p>\u003Cp>\"Wir freuen uns, Berthold und Eduard im Beirat von PlasmidFactory begrüßen zu dürfen\", sagte Dr. Martin Schleef, CEO von PlasmidFactory. \"Bertholds umfangreiche Geschäfts- und Transaktionserfahrung und Eduards fundierte wissenschaftliche Kenntnisse in den Biowissenschaften werden für PlasmidFactory von unschätzbarem Wert sein, da wir unser Wachstum und unsere Expansion in den sich ständig weiterentwickelnden mRNA- und C>-Gebieten fortsetzen, in denen die Herstellung von Plasmiden und Minicircle-DNA eine Schlüsselrolle spielt.\"\u003C/p>\u003Cp>PlasmidFactory hat eine neue HQ (High Quality Grade)-Produktionsanlage eröffnet, die qualitativ hochwertige, hochmoderne Plasmide sowie Minicircle in großem Maßstab herstellt, und arbeitet seit der Partnerschaft mit dem globalen, auf das Gesundheitswesen fokussierten Private-Equity-Unternehmen ARCHIMED im September 2022 aktiv am Aufbau einer GMP (Good Manufacturing Practices)-konformen Anlage, um den Anforderungen des Kundenstamms weiterhin gerecht zu werden.\u003Cbr>Diese sorgfältig geplante Kapazitätserweiterung wird es PlasmidFactory ermöglichen, seinen konkurrenzlosen Ruf als Anbieter von außergewöhnlich hochwertigen und zuverlässigen Ausgangsmaterialien für die Gen- und Zelltherapie sowie für RNA-Impfstoffe weiter zu etablieren und zu nutzen.\u003Cbr>Beide Branchenexperten wurden über ARCHIMEDs MedTalents® rekrutiert, ein globales Netzwerk von assoziierten Führungskräften aus dem Gesundheitswesen, die Geschäfte identifizieren, vermitteln und beraten sowie Portfoliounternehmen betreuen.\u003Cbr>Berthold Hackl ist eine erfolgreiche Führungskraft, Berater und Vorstandsmitglied in den Biowissenschaften im VC, PE und öffentlichen Umfeld und bei verschiedenen Unternehmen im Bereich Biowissenschaften. Er verfügt über mehr als dreißig Jahre Industrieerfahrung in Europa und den USA in den Bereichen Eigenkapitalbeschaffung, Buy-and-Build, Exits und der Entwicklung neuer Märkte.\u003Cbr>Berthold Hackl verfügt über umfangreiche Aufsichtsratserfahrung in Biopharma-, Medizintechnik- und Diagnostikunternehmen. Als General Manager Europe für Eurofins baute er die Biopharma- und Medtech-Plattformen des Unternehmens durch Fusionen und organische Wachstumsinitiativen aus. Zuvor war Hackl für eine Reihe von Unternehmen in der Biopharma- und Medizintechnikbranche tätig, unter anderem als CEO von invendo medical (jetzt AMBU), den strategischen Akteuren Synthes (jetzt J&J) und Biacore (jetzt Danaher).\u003Cbr>\"Als ich in den 80er Jahren zum ersten Mal mit Plasmiden als notwendige Bestandteile von Sequenzierungsprojekten in Berührung kam, hätte ich mir nie träumen lassen, welch zentrale Rolle sie heute in der Entwicklung von Therapien und Impfstoffen einnehmen. Aber schon damals war die Universität Bielefeld eine phänomenale Brutstätte für die Molekularbiologie, und die PlasmidFactory, die es seit über 22 Jahren gibt, gehört seitdem zu ihren bahnbrechenden Sprösslingen\", so Berthold Hackl, heute Beiratsvorsitzender der PlasmidFactory. \"Ich freue mich sehr und bin hoch motiviert, die weitere Entwicklung und den Übergang zur GMP bei diesem anerkannten Marktführer in diesem Bereich zu unterstützen.\"\u003Cbr>Dr. Eduard Ayuso bringt in die PlasmidFactory umfangreiche Erfahrung in der Verwendung von Plasmiden als Ausgangsmaterial für die Herstellung von ATMPs, molekulares Wissen über das Design von AAV-Helferplasmiden und ein internationales Netzwerk von Industrie- und akademischen Experten auf dem Gebiet der Gentherapien ein. Derzeit ist er Chief Technology Officer bei DiNAQOR (Zürich, Schweiz), einem Unternehmen für genetische Medizinplattformen, das sich auf die Behandlung schwerer erblicher Herz- und Nierenkrankheiten konzentriert, und CEO von DINAMIQS (Zürich, Schweiz), einer CDMO, die ein umfassendes Angebot an Produktionsdienstleistungen, Prozessentwicklung, Qualitätskontrolle und Analyselösungen zur Unterstützung und Optimierung der vielversprechendsten Gentherapieprojekte bereitstellt.\u003Cbr>\"Ich kenne Martin Schleef und PlasmidFactory seit fast zwei Jahrzehnten und habe ihre Produkte in einer Vielzahl von Projekten eingesetzt. PlasmidFactory ist ein echter Pionier auf diesem Gebiet, und ich fühle mich geehrt und freue mich, durch die Zusammenarbeit mit ARCHIMED zur nächsten Phase des Unternehmenswachstums beizutragen\", sagte Dr. Ayuso, ein neu ernanntes Beiratsmitglied von PlasmidFactory. Dr. Ayuso war außerdem Leiter der innovativen Vektorologie am französischen Nationalen Institut für Gesundheit und medizinische Forschung (INSERM) und wissenschaftlicher Direktor der Translational Vector Core Unit an der Universität Nantes. Von 2018 bis 2022 war er Vizepräsident der Französischen Gesellschaft für Gen- und Zelltherapie. Er ist Vorsitzender des Herstellungsausschusses der Europäischen Gesellschaft für Gen- und Zelltherapie und Mitglied des Ausschusses für Translationswissenschaft der Amerikanischen Gesellschaft für Gen- und Zelltherapie.\u003C/p>","\u003Cp>\u003Cstrong>Press Release:\u003C/strong>\u003Cbr>The two industry experts are joining PlasmidFactory’s board to further support the strategic development and positioning of the company; their vast industrial and scientific insight will contribute significantly to PlasmidFactory’s growth acceleration.\u003Cbr>“We are pleased to welcome Berthold and Eduard to the PlasmidFactory Board,\" said Dr. Martin Schleef, CEO of PlasmidFactory. \"Berthold’s extensive business and transaction experience, and Eduard’s deep scientific knowledge in life science will be invaluable to PlasmidFactory as we pursue our growth and expansion in the continuously evolving mRNA and C&GT industries where plasmid and minicircle DNA manufacturing play a key role.\"\u003Cbr>PlasmidFactory opened a new HQ (High Quality) production facility that is generating high quality, cutting-edge plasmids as well as minicircles in large scale, and since partnering with global healthcare-focused private equity firm ARCHIMED in September 2022, has been working actively to build a GMP (Good Manufacturing Practices)-compliant facility to continue meeting the needs of the client base.\u003Cbr>This carefully planned capacity expansion will allow PlasmidFactory to further establish and leverage its unrivaled reputation as provider of exceptionally high quality and reliable starting materials for gene and cell therapy as well as RNA vaccines.\u003Cbr>Both industry experts were recruited through ARCHIMED’s MedTalents®, a global network of associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies.\u003Cbr>Berthold Hackl is a successful executive, advisor and board member in the life sciences across VC, PE and public environments and at various life sciences related companies. He brings with him over thirty years of industrial experience in Europe and the US in the areas of equity raising, buy-and-build, exits and the development of new markets.\u003Cbr>\u003C/p>",[700,704],{"url":701,"alt":702},"https://api.plasmidfactory.com/storage/106/responsive-images/Hackl___webp_W___WIDTH____H.webp",{"de":7,"en":703},"Berthold Hackl",{"url":705,"alt":706},"https://api.plasmidfactory.com/storage/107/responsive-images/Ayuso___webp_W___WIDTH____H.webp",{"de":7,"en":707},"Dr. Eduard Ayuso",[],{"headline":710,"subline":711,"description":712,"text":713,"images":715,"files":716},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":714},"\u003Cp>Berthold Hackl has extensive supervisory board experience in biopharma, medtech and diagnostics companies. As General Manager Europe for Eurofins he grew the company’s biopharma and medtech platforms through M&A and organic growth initiatives. Mr. Hackl previously worked for a number of companies in biopharma and medtech, including a role as CEO of invendo medical (now AMBU), strategic players Synthes (now J&J) and Biacore (now Danaher).\u003Cbr>“When I first encountered plasmids as necessary parts of sequencing projects in the 80ies, I would have never dreamt about the pivotal place they now occupy at the forefront of therapeutic and vaccine development. But even at that time, the University of Bielefeld was already a phenomenal breeding ground for molecular biology, and PlasmidFactory, who has been around for over 22 years, has ever since been one of its pioneering offsprings” said Berthold Hackl, now Chairman of PlasmidFactory. “I am very excited and deeply motivated to support the further development and move into GMP of this recognized leader in the field.”\u003Cbr>Dr. Eduard Ayuso brings to PlasmidFactory an extensive experience in the use of plasmids as starting materials for manufacturing ATMPs, molecular knowledge on the design of AAV helper plasmids and an international network of industry and academic experts in the field of gene therapies. He is currently the Chief Technology Officer at DiNAQOR (Zürich, Switzerland), a genetic medicine platform company focused on addressing severe inherited cardiac and kidney diseases and CEO of DINAMIQS (Zurich, Switzerland) a CDMO providing a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and optimize the most promising gene therapy projects.\u003Cbr>“I know Martin Schleef and PlasmidFactory for almost two decades and have been using their products in a variety of projects. I have been always impressed by the quality and the scientific knowledge of the team; PlasmidFactory is a true industry pioneer in the field and I am honored and excited to contribute to the next phase of the company growth by teaming up with ARCHIMED” said Dr Ayuso, a newly appointed Board Member of PlasmidFactory. Dr. Ayuso has also served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at University of Nantes. From 2018 to 2022, he has served as Vice President of the French Society for Gene and Cell Therapy. He is the chairman of the Manufacturing committee of the European Society for Gene and Cell Therapy and member of the Translational Science committee of the American Society for Gene and Cell Therapy.\u003C/p>",[],[],{"type":56,"title":718,"slug":721,"place":724,"description":726,"date":728,"links":729,"claim":734,"content":736},{"de":719,"en":720},"ArchiMed investiert in PlasmidFactory","ARCHIMED invests in PlasmidFactory",{"de":722,"en":723},"archimed-investiert-in-plasmidfactory","archimed-invests-in-plasmidfactory",{"de":7,"en":725},"Bielefeld/Lyon",{"de":727,"en":720},"ARCHIMED investiert in PlasmidFactory","2022-09-28",[730],{"title":731,"target":733},{"de":7,"en":732},"Archimed Group","https://www.archimed.group/",{"de":7,"en":735},"By partnering with a strong player like ARCHIMED, PlasmidFactory advances expansion to GMP-compliant production of plasmid and minicircle DNA",[737,752],{"headline":738,"subline":740,"description":741,"text":742,"images":744,"files":751},{"de":7,"en":739},"ArchiMed invests in PlasmidFactory, a German gene and cell therapy specialist",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":743},"\u003Cp>\u003Cstrong>Press Release\u003C/strong>\u003Cbr>September 28, 2022 - Trans-Atlantic private equity healthcare specialist ArchiMed has invested in Bielefeld, Germany-based PlasmidFactory. Founded in 2000, PlasmidFactory is the leading contract manufacturer and service provider for plasmid and minicircle DNA. PlasmidFactory develops and manufactures exceptionally high-grade plasmids and minicircles, used to modify cells and produce viral gene therapy vectors like AAV, LV and mRNA for combating everything from viruses like COVID-19 to seemingly intractable diseases like cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDs (including CAR-T cell applications). Plasmids are notably a key component for the production of mRNA COVID-19 vaccines. \u003C/p>\u003Cp>PlasmidFactory is the second buy-and-build investment of ArchiMed’s MED Platform II fund, which began fundraising in January. The fund currently exceeds in size its predecessor fund, the fully-invested, €1.5 billion MED Platform I fund. A final target size for MED Platform II has not been disclosed.\u003C/p>\u003Cp>“Plasmids, and cell and gene therapies in general, offer enormous potential to improve healthcare,” says ArchiMed partner Loïc Kubitza.  “Combining ArchiMed’s financial power and international healthcare network with PlasmidFactory’s know-how and processes should scale up the group’s production and sales.” \u003C/p>\u003Cp>“Even with accelerated roll-outs, demand for plasmids is likely to vastly exceed supply for years to come,” says Dr. Martin Schleef, founder and CEO of PlasmidFactory. “ArchiMed will act as our key catalyst for rapid and efficient expansion in a highly complex domain that few generalist investors and few healthcare investors, understand.” Schleef and his management team will remain in place, with the former rolling over a substantial portion of his proceeds in the group.\u003C/p>\u003Cp>PlasmidFactory has seen its revenues grow an average of 100 percent annually since 2019. The company opened a new HQ (High Quality) production facility in May, 2022 that generates exceptionally pure, cutting-edge plasmids. With the investment and support of ArchiMed, PlasmidFactory will shortly fund the construction of an even larger GMP (Good Manufacturing Practices) compliant facility. “At the heart of this deal is an opportunity to leverage through carefully planned expansion PlasmidFactory’s unrivaled reputation as provider of exceptionally pure materials for gene and cell therapy,” says ArchiMed partner Antoine Faguer. “The synergistic effects of the ArchiMed portfolio network, now including PlasmidFactory, will significantly contribute to the acceleration of clinical research with DNA of the highest [GMP] quality,” adds Dr. Schleef.\u003C/p>\u003Cp>The MED Platform funds partner with growing companies in the European and North American mid-cap healthcare sectors, buying stakes in companies, in association with existing owners and managers. The funds provide companies with the strategic, tactical and financial resources they need to broaden product lines and expand into new regions, organically and through acquisitions.\u003C/p>\u003Cp>MED Platform II has raised in excess of €2 billion since launching fundraising in January, which makes it one of the largest healthcare buyout funds at a global level and the largest ever in Europe. It has an investor re-up rate of almost 100 percent, with the typical commitment larger than the average commitment to MED Platform I. MED Platform II will target 10 to 12 investments versus the seven MED Platform I targeted. MED Platform II has attracted a wide-range of institutional and family office investors, with respectively 50 percent, 40 percent and 10 percent coming from Europe, North America and the Asia-Pacific region. In July, MED Platform II made its first acquisition, a $1.1 billion take-private purchase of Nasdaq-listed Natus Medical, a global leader in neurodiagnostic devices. \u003C/p>\u003Cp>MED Platform I closed on commitments of €1.5 billion in 2020 (€1.0 billion excluding co-investment vehicles), then a record for a Europe-based private equity healthcare fund. The fund has distributed 70 percent of its invested capital. Its total performance stands at 2.2 times invested capital, equal to a 69 percent annualized return. This makes MED Platform I a top-decile performer for all buyout funds launched in 2019, according to Preqin data. ArchiMed’s smallcap fund, MED II, is also a top-decile buyout fund performer for the 2018 vintage. Its predecessor smallcap fund, MED I, is the best performing buyout fund in the world for the 2014 vintage.\u003C/p>",[745,748],{"url":746,"alt":747},"https://api.plasmidfactory.com/storage/104/responsive-images/Archimed___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":749,"alt":750},"https://api.plasmidfactory.com/storage/105/responsive-images/PF-Logo___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":753,"subline":755,"description":756,"text":757,"images":759,"files":760},{"de":7,"en":754},"About ArchiMed ",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":758},"\u003Cp>With offices in the US and Europe, ArchiMed is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ArchiMed to serve as both a strategic and financial partner to North American and European healthcare businesses. Prioritized areas of focus include Biopharmaceutical Products & Services, Life Science Tools, Medical Devices & Technologies, Diagnostics, Health Technologies & Software and Consumer Health. ArchiMed helps partners internationalize, acquire, innovate and expand their products and services. Over the last twenty years, ArchiMed’s leadership team has directly managed and invested in over eighty small- to large-size healthcare companies globally, representing over €50 billion of combined value. ArchiMed manages more than €5 billion across its various funds. Since inception, ArchiMed has been a committed impact investor, both directly and through its Eurêka Foundation.\u003C/p>\u003Cp>Contacts - France: Stéphanie du Ché, \u003Ca target=\"_blank\" href=\"mailto:stephanie.duche@archimed.group\" tt-mode=\"url\">stephanie.duche@archimed.group\u003C/a>, +33 (0)6 16 36 11 08; \u003C/p>\u003Cp>International: David Lanchner, \u003Ca target=\"_blank\" href=\"mailto:dlanchner@lanchner.com\" tt-mode=\"url\">dlanchner@lanchner.com\u003C/a>, +33 (0)6 33 43 50 76\u003C/p>\u003Cp>\u003C/p>",[],[],{"type":56,"title":762,"slug":765,"place":767,"description":768,"date":771,"links":772,"claim":781,"content":783},{"de":763,"en":764},"2 Publications in \"Gene Therapy Of Cancer – Methods and Protocols\"","Publications in \"Gene Therapy Of Cancer – Methods and Protocols\"",{"de":766,"en":766},"2-publications-in-gene-therapy-of-cancer-methods-and-protocols",{"de":7,"en":447},{"de":769,"en":770},"Zwei Veröffentlichungen in \"Gene Therapy Of Cancer – Methods and Protocols\"","Two Publications in \"Gene Therapy Of Cancer – Methods and Protocols\"","2022-07-14",[773,777],{"title":774,"target":776},{"de":7,"en":775},"Minicircles for CAR T Cell Production by Sleeping Beauty Transposition","https://link.springer.com/protocol/10.1007/978-1-0716-2441-8_2",{"title":778,"target":780},{"de":7,"en":779},"CGE for Quality Control of Plasmid DNA in Gene Therapy","https://link.springer.com/protocol/10.1007/978-1-0716-2441-8_17",{"de":7,"en":782},"We thank the editor Wolfgang Walther for his great work in the new edition of this informative book and the invitation to participate.",[784],{"headline":785,"subline":787,"description":788,"text":789,"images":791,"files":795},{"de":786,"en":786},"The latest edition of this book with new, promising approaches …",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":790},"\u003Cp>in the fight against cancer has just been published. This time, we from the PlasmidFactory are represented with two contributions. We thank the editor Wolfgang Walther for his great work in the new edition of this informative book and the invitation to participate.\u003C/p>\u003Cp>\u003Cstrong>Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview\u003C/strong>\u003Cbr>Minicircle DNA for a CAR transgene in the form of a Sleeping Beauty transposon, and minicircle for SB transposase gene, both produced by PlasmidFactory prove successful in efficiently generating CAR T cells against B-cell malignancies.\u003Cbr>\u003Cem>Authors: Sabrina Prommersberger, Razieh Monjezi, Ram Shankar, Marco Schmeer, Michael Hudecek, Zoltán Ivics et al.\u003C/em>\u003Cbr>\u003Cbr>\u003Cstrong>Capillary Gel Electrophoresis (CGE) for Quality Control of Plasmid DNA in Gene Therapy: Quality Control of 20 Years Stored GMP-Grade Plasmid DNA\u003C/strong>\u003Cbr>Capillary Gel Electrophoresis proves to be a powerful analytical QC tool for measuring the stability of plasmid DNA under long-term storage.\u003Cbr>\u003Cem>Authors: Marco Schmeer, Martin Schleef, Ram Shankar, Dennis Kobelt, Wolfgang Walther\u003C/em>\u003C/p>",[792],{"url":793,"alt":794},"https://api.plasmidfactory.com/storage/103/responsive-images/GeneTherapyOfCancer___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":56,"title":797,"slug":799,"place":801,"description":803,"date":806,"links":807,"claim":816,"content":817},{"de":798,"en":798},"Certificat de CIR",{"de":800,"en":800},"certificat-de-cir",{"de":7,"en":802},"Paris/Bielefeld",{"de":804,"en":805},"PlasmidFactory ist CIR-registriert durch das französische Ministerium für nationale Bildung, Hochschulwesen und Forschung.","PlasmidFactory is CIR-registered by the French Ministere de L´Education Nationale, de L´Enseignement Superieure et de la Recherche.","2022-04-28",[808,812],{"title":809,"target":811},{"de":7,"en":810},"More about Certificat de CIR","https://www.enseignementsup-recherche.gouv.fr/fr/credit-impot-recherche-cir-50180",{"title":813,"target":815},{"de":7,"en":814},"The open-data lists are available here :","https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-cir-et-cii-organismes-et-bureaux-de-style-agrees/table/?q=Plasmidfactory",{"de":7,"en":805},[818,830],{"headline":819,"subline":821,"description":822,"text":823,"images":825,"files":829},{"de":7,"en":820},"Research meets business",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":824},"\u003Cp>\u003Cstrong>INFORMATION\u003C/strong>\u003Cbr>This document is for your information and has no legal value\u003Cbr>We received your request to be approved as an organisation carrying out R&D activities for the account of private companies. We reviewed the documentation you sent us and we are pleased to let you know that your request has been approved. Please find, here enclosed, the decision of approval.\u003Cbr>We would be grateful if you could keep us informed of any significant modification of your activity or competences. Such an evolution would require a re-examination of your application.\u003C/p>\u003Cp>Information on your activity (address, contact data, field of expertise and years for which you are approved) wiII be included in the Iist of private research organisations approved by the French Ministry of Higher Education, Research and Innovation, which is published on Internet (address below). If you wish so, you may nevertheless ask the Département des politiques d’incitation à la R&D des entreprises not to include your organisation in this list.\u003C/p>\u003Cp>\u003C/p>\u003Cp>\u003C/p>",[826],{"url":827,"alt":828},"https://api.plasmidfactory.com/storage/102/responsive-images/FrzMinistere___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":831,"subline":832,"description":833,"text":834,"images":836,"files":837},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":835},"\u003Cp>La Ministre de l’Enseignement supérieur, de la Recherche et de l’Innovation,\u003Cbr>Vu l'article 244 quater B du code général des impôts,\u003Cbr>Vu la demande présentée par l’organisme,\u003Cbr>Décide d’accorder l’agrément prévu au II d bis de l'article 244 quater B du code général des impôts pour les organismes de recherche privés, à :\u003Cbr>PLASMIDFACTORY GMBH & CO. KG\u003Cbr>D-33607 Bielefeld -ALLEMAGNE\u003Cbr>Cet agrément est accordé au titre des années : 2022,2023,2024.\u003Cbr>Le renouvellement de cet agrément se fera sur demande expresse, avant le terme de la dernière année.\u003C/p>\u003Cp>\u003C/p>",[],[],{"type":56,"title":839,"slug":841,"place":843,"description":844,"date":847,"links":848,"claim":849,"content":850},{"de":840,"en":840},"New tools to support AAV manufacturing",{"de":842,"en":842},"new-tools-to-support-aav-manufacturing",{"de":7,"en":447},{"de":845,"en":846},"Optimierung der AAV-Produktion mit unserem exklusiven 2-Plasmid-System","Optimisation of AAV production with our exclusive, our 2-Plasmid-System","2021-11-10",[],{"de":7,"en":846},[851,863],{"headline":852,"subline":854,"description":855,"text":856,"images":858,"files":862},{"de":7,"en":853},"In-Stock Services for Helper & Packaging and vector plasmids ",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":857},"\u003Cp>With the rapid developments in the field of gene therapy, the use of viral vectors, especially AAV, to treat various monogenic, inherited diseases in human patients is gaining momentum. Nonetheless, there are still options to optimize the production of such vectors in mammalian cells.\u003C/p>\u003Cp>PlasmidFactory is the exclusive worldwide provider of a 2-Plasmid-System for production of AAV vectors and holds the exclusive license from the German Cancer Research Centre (DKFZ) for global production, distribution and use of Helper & Packaging Plasmids of the pDG and pDP family.\u003C/p>\u003Cp>We offer a large variety of Helper & Packaging plasmids for the production of serotype-specific AAV vectors. These plasmids are available from our In-Stock Service.\u003C/p>\u003Cp>\u003C/p>",[859],{"url":860,"alt":861},"https://api.plasmidfactory.com/storage/101/responsive-images/2ps-kompakt___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":864,"subline":866,"description":867,"text":868,"images":870,"files":871},{"de":7,"en":865},"AAV as important tool in the field of gene therapy",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":869},"\u003Cp>Advances in the field of gene therapy have demonstrated the potential of viral vectors to treat various monogenic, inherited diseases in human patients. Thanks to their unique characteristics, recombinant vectors derived from adeno-associated virus (AAV) represent a particularly effective means of delivering therapeutic genes to their targets.\u003C/p>\u003Cp>Optimizing production of these recombinant AAV vectors to meet the demand for increasingly large quantities, while maintaining quality and cost-effectiveness, is a key challenge. \u003C/p>",[],[],{"type":56,"title":873,"slug":876,"place":878,"description":879,"date":882,"links":883,"claim":884,"content":886},{"de":874,"en":875},"Scaling up: products of the highest purity in large quantities","Press Release: Scaling up – products of the highest purity in large quantities",{"de":877,"en":877},"scaling-up-products-of-the-highest-purity-in-large-quantities",{"de":7,"en":447},{"de":880,"en":881},"Unterstützt: Scaling up - Produkte von höchster Reinheit in großen Mengen","Supported: Scaling up – products of the highest purity in large quantities","2021-01-22",[],{"de":7,"en":885},"Due to the limited global availability of the key substance DNA for the pharmaceutical production of vaccines, there is an extraordinary and long-lasting need.",[887,902],{"headline":888,"subline":890,"description":891,"text":892,"images":894,"files":901},{"de":7,"en":889},"Biotechnology company from East Westphalia moves into the spotlight by expanding its capacity to participate in vaccine production.",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":893},"\u003Cp>\u003Cstrong>Press Release. \u003C/strong>\u003Cbr>PlasmidFactory GmbH (Bielefeld), based in Bielefeld since 2000, has been working closely with leading global mRNA manufacturers for many years and produces plasmid DNA as an essential starting material for their vaccine production, which has proven to be extremely effective in the corresponding (pre-)clinical studies.\u003Cbr>On 22 January, Minister Prof. Pinkwart from the Ministry of Economic Affairs, Innovation, Digitalisation and Energy of North Rhine-Westphalia (MWIDE) accepted the invitation to get to know the company - unfortunately only virtually due to coronavirus - to take a virtual tour to the production facilities and take a look at the expansion areas which will be used for new production capacities for the manufacture of plasmid DNA, as a key substrate for the production of mRNA vaccines - e.g. Covid19 vaccines.\u003C/p>\u003Cp>Since the beginning of the Covid19 pandemic, the PlasmidFactory has postponed numerous projects concerning regular DNA production planned for 2020 to immediately help meeting the enormous demand for DNA of this High Quality level.\u003C/p>\u003Cp>\u003Cstrong>New capacity through expansion\u003C/strong>\u003Cbr>The PlasmidFactory is therefore now planning to establish a production facility in an exceptionally short space of time that can produce the enormous quantities of plasmid DNA that are currently urgently needed to support the pharmaceutical production of the Covid19 vaccine and enable an expansion of the customers' production capacities. \u003Cbr>The funding promised by the state of North Rhine-Westphalia will help to make these enormous efforts and expenses possible here in OWL in the short term. \u003Cbr>The strategy known as mRNA vaccine for protection against the CoV-2 virus, but also against any other pandemics caused by viral pathogens that may be expected in the future, is without alternative from the company's perspective in terms of the expected patient safety. The speed of development is also particularly important here, as the mRNA vaccine is based on DNA, which can be produced very quickly, but in the past could not be produced to the high quality standards that are now in demand.\u003Cbr>Specifically, a modular plasmid DNA production facility is to be built on the site next to the PlasmidFactory, which is to be equipped as a high-performance laboratory for DNA production within a few months, so that the - currently steadily increasing - demand for starting substrate for vaccine production can be met in Bielefeld from the summer.\u003Cbr>Thanks to the modular design, prefabricated room sections can be quickly combined to form a production unit in which the manufacturing process with fermentation, extraction and purification of the plasmid DNA, including media preparation and storage capacity, can take place.\u003C/p>",[895,898],{"url":896,"alt":897},"https://api.plasmidfactory.com/storage/99/responsive-images/Gefoerdert-NRW___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":899,"alt":900},"https://api.plasmidfactory.com/storage/100/responsive-images/Fermenter___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":903,"subline":905,"description":906,"text":907,"images":909,"files":910},{"de":7,"en":904},"Long-term global demand",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":908},"\u003Cp>Since 2000, the PlasmidFactory has specialised in producing DNA of exceptionally high purity for research in the field of gene therapy and genetic vaccines and works with universities, biotechnology and pharmaceutical companies worldwide both scientifically and as a supplier. The entire production as well as the research and development department is bundled at the Bielefeld site. There is very close co-operation with Bielefeld University, which ensures the availability of highly motivated young employees as well as an involvement in current research topics and technologies. \u003C/p>\u003Cp>Due to the worldwide limited availability of auxiliary and starting materials and especially the key substance DNA for the pharmaceutical production of the vaccine, there is an extraordinary and long-lasting demand for it, which could therefore be met within North Rhine-Westphalia (as well as Germany and the European Community). The PlasmidFactory can provide an independent supply of the currently most important raw material for mRNA production or ensure its availability.\u003C/p>",[],[],{"type":5,"title":912,"slug":914,"place":916,"description":917,"date":918,"links":919,"claim":920,"content":922},{"de":913,"en":913},"Production of plasmid DNA as starting material for mRNA vaccines",{"de":915,"en":915},"production-of-plasmid-dna-as-starting-material-for-mrna-vaccines",{"de":7,"en":447},{"de":7,"en":7},"2021-01-15",[],{"de":7,"en":921},"High quality DNA with the requirements to perform as starting material for the production of RNA used in clinical applications",[923,937],{"headline":924,"subline":926,"description":927,"text":928,"images":930,"files":936},{"de":7,"en":925},"How has the importance of plasmid DNA for pharmaceutical applications changed due to the increasing production of gene therapy vectors and COVID-19 mRNA drugs? ",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":929},"\u003Cp>Plasmids are used, for example, as starting material for the production of viral vectors (AAV, Lenti, etc.) and for the production of RNA. In particular, the production of plasmid DNA as a starting material for the production of RNA vaccines has become increasingly important, especially in the context of the COVID-19 pandemic situation, as RNA is considered a promising vaccine candidate for the prevention of certain viral infections and has the advantage of neither integrating into the genome of the cell nor remaining in the patient's body as a potentially effective molecule in the long term.\u003C/p>",[931,934],{"url":932,"alt":933},"https://api.plasmidfactory.com/storage/91/responsive-images/corona-virus___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":7,"alt":935},{"de":7,"en":7},[],{"headline":938,"subline":940,"description":941,"text":942,"images":944,"files":945},{"de":7,"en":939},"Interview from BioTechnologie Yearbook 2020  with Dr. Martin Schleef, CEO, PlasmidFactory GmbH ",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":943},"\u003Cp>What expertise and experience does PlasmidFactory have in the production of plasmid DNA for pharmaceutical application? \u003C/p>\u003Cp>Thanks to its 20 years of experience in the field of DNA production, PlasmidFactory has an established process for the production of corresponding plasmid DNA, which fulfils the requirements to be used as a starting material for the production of such RNA used in clinical applications: High Quality Grade Plasmid DNA. This plasmid DNA is produced in a special facility: Starting from a characterised cell bank (RCB), the manufacturing process goes through various well-documented production steps. The HQ fermentation plant is physically separated from the purification (chromatography) to ensure that the downstream processing of the sensitive DNA is not affected by live contamination. The proprietary special, patented digestion and purification process results in a high level of pure, supercoiled (ccc) plasmid monomers that meet regulatory requirements to form a defined, homogeneous product that undergoes a series of quality controls (QCs) for the cell bank and plasmid DNA product prior to release. The corresponding QC report is then part of the delivered product alongside the release certificate.\u003C/p>\u003Cp>What quality parameters do PlasmidFactory products offer? \u003C/p>\u003Cp>In contrast to previously available processes, which were sufficient for the production of plasmid DNA for research in terms of quality and quantity, a process must now be developed that enables plasmids to be produced both in High Quality Grade and in sufficient quantities. Due to the high quality requirements, this represents a considerable challenge that currently needs to be solved in the area of fermentation as well as chromatographic processing of the DNA product. Due to our expertise, particularly in these areas, we see the PlasmidFactory in a pioneering role - we are happy to take on this challenge - very successfully so far!\u003C/p>\u003Cp>\u003C/p>",[],[],{"type":5,"title":947,"slug":949,"place":951,"description":952,"date":953,"links":954,"claim":955,"content":957},{"de":7,"en":948},"Plasmid DNA production on a large scale in High Quality Grade",{"de":7,"en":950},"lasmid-dna-production-on-a-large-scale-in-high-quality-grade",{"de":7,"en":447},{"de":7,"en":7},"2021-01-12",[],{"de":7,"en":956},"The proprietary special purification process results in a high level of pure, supercoiled (ccc) plasmid monomers that meet regulatory requirements to form a defined, homogeneous product",[958],{"headline":959,"subline":960,"description":961,"text":962,"images":964,"files":971},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":963},"\u003Cp>\u003Cstrong>Required measures due to the corona pandemic: Plasmid DNA production on a large scale in High Quality Grade\u003C/strong>\u003Cbr>Plasmid DNA-based vectors are used for the transfer of genetic information into target cells. In addition to its use as an active ingredient to complement genetic defects in the context of cell and gene therapy, DNA-based immunisation, e.g. against viruses, pathogenic germs or tumour tissue (genetic vaccination), the activation of new tissue formation or the support of tissue regeneration are further clinical fields of application for plasmid DNA. The plasmids carry the gene sequences for intracellular production of the coded proteins. \u003C/p>\u003Cp>Plasmids also serve as starting material for the production of viral vectors (AAV, Lenti etc.) and for the production of RNA. In particular, the production of plasmid DNA as starting material for the production of RNA vaccines has become increasingly important, especially in the context of the COVID-19 pandemic, as RNA is considered a promising vaccine candidate for the prevention of certain viral infections and has the advantage of neither integrating into the genome of the cell nor remaining in the patient's body as a potentially effective molecule in the long term.\u003C/p>\u003Cp>The PlasmidFactory has a process for the production of corresponding plasmid DNA, which fulfils the requirements to be used as starting material for the production of such RNA used in clinical applications: High Quality Grade Plasmid DNA. This plasmid DNA is produced in a special facility. Starting from a characterised cell bank (RCB), the production process goes through various well-documented production steps. The HQ fermentation plant is physically separated from the purification (chromatography) to ensure that the downstream processing of the sensitive DNA is not affected by live contamination. The proprietary special purification process results in a high level of pure, supercoiled (ccc) plasmid monomers that meet regulatory requirements to form a defined, homogeneous product that undergoes a series of quality controls for the cell bank and plasmid DNA product prior to release.\u003C/p>\u003Cp>In contrast to previously available processes, which were qualitatively and quantitatively sufficient for the production of plasmid DNA for research purposes, a process must now be developed through which plasmids can be produced as high quality grade in sufficient quantities. Due to the high quality requirements, this represents a major challenge that currently needs to be solved both in the area of fermentation as well as chromatographic processing of the DNA product. Thanks to its expertise, PlasmidFactory has a pioneering role to play here - a challenge we are happy to take on.\u003C/p>",[965,968],{"url":966,"alt":967},"https://api.plasmidfactory.com/storage/92/responsive-images/big-aekta___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":969,"alt":970},"https://api.plasmidfactory.com/storage/93/responsive-images/big-bottle___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":5,"title":973,"slug":975,"place":977,"description":978,"date":953,"links":979,"claim":980,"content":981},{"de":974,"en":974},"Required measures due to the corona pandemic: Plasmid DNA production on a large scale in High Quality Grade",{"de":976,"en":976},"required-measures-due-to-the-corona-pandemic-plasmid-dna-production-on-a-large-scale-in-high-quality-grade",{"de":7,"en":447},{"de":948,"en":948},[],{"de":7,"en":956},[982,996],{"headline":983,"subline":984,"description":985,"text":986,"images":988,"files":995},{"de":7,"en":948},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":987},"\u003Cp>Plasmid DNA-based vectors are used for the transfer of genetic information into target cells. In addition to its use as an active ingredient to complement genetic defects in the context of cell and gene therapy, DNA-based immunisation, e.g. against viruses, pathogenic germs or tumour tissue (genetic vaccination), the activation of new tissue formation or the support of tissue regeneration are further clinical fields of application for plasmid DNA. The plasmids carry the gene sequences for intracellular production of the coded proteins.\u003C/p>\u003Cp>Plasmids also serve as starting material for the production of viral vectors (AAV, Lenti etc.) and for the production of RNA. In particular, the production of plasmid DNA as starting material for the production of RNA vaccines has become increasingly important, especially in the context of the COVID-19 pandemic, as RNA is considered a promising vaccine candidate for the prevention of certain viral infections and has the advantage of neither integrating into the genome of the cell nor remaining in the patient's body as a potentially effective molecule in the long term.\u003C/p>",[989,992],{"url":990,"alt":991},"https://api.plasmidfactory.com/storage/49/responsive-images/big-aekta___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":993,"alt":994},"https://api.plasmidfactory.com/storage/50/responsive-images/big-bottle___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":997,"subline":998,"description":999,"text":1000,"images":1002,"files":1003},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1001},"\u003Cp>The PlasmidFactory has a process for the production of corresponding plasmid DNA, which fulfils the requirements to be used as starting material for the production of such RNA used in clinical applications: High Quality Grade Plasmid DNA. This plasmid DNA is produced in a special facility. Starting from a characterised cell bank (RCB), the production process goes through various well-documented production steps. The HQ fermentation plant is physically separated from the purification (chromatography) to ensure that the downstream processing of the sensitive DNA is not affected by live contamination. The proprietary special purification process results in a high level of pure, supercoiled (ccc) plasmid monomers that meet regulatory requirements to form a defined, homogeneous product that undergoes a series of quality controls for the cell bank and plasmid DNA product prior to release.\u003C/p>\u003Cp>In contrast to previously available processes, which were qualitatively and quantitatively sufficient for the production of plasmid DNA for research purposes, a process must now be developed through which plasmids can be produced as high quality grade in sufficient quantities. Due to the high quality requirements, this represents a major challenge that currently needs to be solved both in the area of fermentation as well as chromatographic processing of the DNA product. Thanks to its expertise, PlasmidFactory has a pioneering role to play here - a challenge we are happy to take on.\u003C/p>",[],[],{"type":56,"title":1005,"slug":1007,"place":1009,"description":1010,"date":1011,"links":1012,"claim":1013,"content":1014},{"de":1006,"en":1006},"20 years of PlasmidFactory",{"de":1008,"en":1008},"20-years-of-plasmidfactory",{"de":7,"en":447},{"de":1006,"en":1006},"2020-12-14",[],{"de":7,"en":7},[1015],{"headline":1016,"subline":1018,"description":1019,"text":1020,"images":1022,"files":1029},{"de":7,"en":1017},"We are proud of this and are doing everything technically and humanly possible for this important feat!",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1021},"\u003Cp>Today, the PlasmidFactory has 27 employees and is currently working at full speed and on an exceptional scale on the production of components for vaccine production in addition to scientific research and optimization. \"We are proud of this and are doing everything technically and humanly possible for this important feat!\" says Dr. Martin Schleef about the status of production.\u003C/p>\u003Cp>No less important is the company's outstanding contribution to research in the field of cancer therapy. PlasmidFactory has developed and patented a method with which so-called CAR-T cells can be produced. In contrast to conventional methods, this does not use viral vectors, but PlasmidFactory's proprietary minicircle technology.  Corresponding products are currently undergoing clinical trials and initial successes have already been reported.\u003C/p>\u003Cp>We would like to thank the German Federal Ministry of Education and Research (BMBF), the German Federal Ministry of Economics and Technology (BMWi) and the European Commission (CLINIGENE network of excellence) for their financial and content-related support of our research activities, which have led to a successful expansion of our product range.\u003C/p>\u003Cp>The PlasmidFactory team is delighted that OWL is moving to the center of biotechnology and knows how to celebrate its 20th anniversary - under corona conditions, of course!\u003C/p>",[1023,1026],{"url":1024,"alt":1025},"https://api.plasmidfactory.com/storage/97/responsive-images/20Jahre-pf___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":1027,"alt":1028},"https://api.plasmidfactory.com/storage/98/responsive-images/TZ-PF-Bielefeld___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":56,"title":1031,"slug":1033,"place":1035,"description":1037,"date":1039,"links":1040,"claim":1045,"content":1047},{"de":1032,"en":1032},"Cooperation between PlasmidFactory and MDCell continues",{"de":1034,"en":1034},"cooperation-between-plasmidfactory-and-mdcell-continues",{"de":7,"en":1036},"Bielefeld/Berlin/Germany",{"de":1038,"en":1032},"Zusammenarbeit zwischen PlasmidFactory und MDCell wird fortgesetzt","2020-11-09",[1041],{"title":1042,"target":1044},{"de":7,"en":1043},"mdc-berlin","https://www.mdc-berlin.de/",{"de":7,"en":1046},"The MDCell Helmholtz Innovation Lab is now extending its collaboration with PlasmidFactory to optimize the \"Sleeping Beauty\" system.",[1048,1063],{"headline":1049,"subline":1051,"description":1052,"text":1053,"images":1055,"files":1062},{"de":7,"en":1050},"Sleeping Beauty 100x",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1054},"\u003Cp>If you want to modify immune cells in the human body so that they can effectively fight a tumor or slow down an autoimmune disease, for example, you need reliable and safe tools. One of these is the \"Sleeping Beauty\" system developed at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). The MDCell Helmholtz Innovation Lab and the biopharmaceutical company PlasmidFactory are jointly preparing this system so that it will be suitable for gene therapy in the clinic in the future. The two partners have now extended their collaboration for a further two years. \u003C/p>\u003Cp>\"Sleeping Beauty 100x\" is based on an element in the genetic material of fish that presumably copied itself 20 million years ago as a \"jumping gene\" (transposon) and was able to repeatedly insert itself into new positions in the fish DNA. Transposons mix up the genome and are therefore regarded as one of the motors of evolution. Dr. Zsuzsanna Izsvák and her colleagues have awakened the jumping gene from its evolutionary slumber, increased its activity 100-fold and made it usable for gene therapy. The \"Sleeping Beauty\" system can now introduce genes into the genome. It is safer, cheaper and more efficient than other methods, Izsvák emphasizes.\u003C/p>\u003Cp>The modified gene sequence does not need a virus as a \"cab\" (vector) to its destination. The disadvantages associated with viruses in gene therapy are therefore eliminated. Instead, the system consists of two elements: the transposon pT4 - a ring-shaped DNA molecule (plasmid) in which the desired gene is inserted between two typical markers - and the genetic material for an enzyme called \"SB100x\", which cuts the desired gene out of the plasmid and guides it to its destination.\u003C/p>",[1056,1059],{"url":1057,"alt":1058},"https://api.plasmidfactory.com/storage/95/responsive-images/MDClogo-RGB-blau-weiss-EN___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":1060,"alt":1061},"https://api.plasmidfactory.com/storage/96/responsive-images/PF-Logo___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":1064,"subline":1066,"description":1067,"text":1068,"images":1070,"files":1071},{"de":7,"en":1065},"Proven collaboration",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1069},"\u003Cp>MDCell and PlasmidFactory are further refining the system to make its use in human cells even safer. For example, the genetic material for the enzyme \"SB100x\" is already transcribed in the Petri dish and added to the cells to be modified as in vitro transcribed RNA (IVT RNA). The transposon \"pT4\" is also no longer a complete plasmid, as is often the case in bacteria. Instead, the PlasmidFactory has developed a technique in which a mini-ring (minicircle) is formed. Apart from the necessary markers, it consists almost entirely of the gene that is to be inserted. \u003C/p>\u003Cp>\"It is very important that the bacterial parts of the plasmids are omitted - to further improve the safety and efficacy of the SB100x transposon system,\" says Dr. Holger Hoff, head of MDCell. \"And PlasmidFactory produces particularly high-quality minicircles, as they are very tightly twisted.\" \u003C/p>\u003Cp>Both partners have extensive expertise. PlasmidFactory has know-how in the design and duplication of the \"gene cabs\", in patent issues and questions of approval. \"We are currently establishing high-quality production processes for minicircle DNA in our special laboratory in Bielefeld, which are used for CAR-T cell therapy research,\" explains Dr. Martin Schleef, Managing Director of PlasmidFactory. MDCell, in turn, combines the research of various working groups with partners from industry, develops processes and provides rooms and equipment. Their common goal is to use Sleeping Beauty to genetically modify immune cells, for example, so that they can help patients again and make the system ready for clinical use. To achieve this, it must not only be safe, it must also be possible to mass produce it in consistent quality. \"We are working together to establish the relevant protocols for GMP facilities,\" says Hoff.\u003C/p>\u003Cp>\u003C/p>",[],[],{"type":5,"title":1073,"slug":1075,"place":1077,"description":1078,"date":1081,"links":1082,"claim":1083,"content":1085},{"de":7,"en":1074},"Customized MIDGE® DNA",{"de":7,"en":1076},"customized-midge-dna",{"de":7,"en":7},{"de":1079,"en":1080},"PlasmidFactory hält die weltweiten Markenrechte für die MIDGE-Technologie","PlasmidFactory holds the worldwide trademark rights for the MIDGE technology","2020-06-06",[],{"de":7,"en":1084},"PlasmidFactory holds the worldwide trademark rights for the MIDGE technology.",[1086,1101],{"headline":1087,"subline":1089,"description":1090,"text":1091,"images":1093,"files":1100},{"de":7,"en":1088},"Minimized DNA in linear form with caps",{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1092},"\u003Cp>An alternative concept for the production of minimal DNA vectors, which contain only the information necessary for the intended effect, is e.g. MIDGE® (minimal immunologically defined gene expression) DNA. The MIDGE structure is linear and tightly closed by single-stranded hairpin regions at both ends. This leads to the characteristic small size of these molecules, which – like the minicircles – have already been used in preclinical research as well as in clinical studies. \u003C/p>\u003Cp>However, such linear molecules do not have the superhelicity characteristic of intact plasmids and PlasmidFactory‘s minicircles, so that minicircle DNA is, in our view, the preferred system when choosing a suitable DNA vector.\u003C/p>",[1094,1097],{"url":1095,"alt":1096},"https://api.plasmidfactory.com/storage/113/responsive-images/Midge-links___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":1098,"alt":1099},"https://api.plasmidfactory.com/storage/114/responsive-images/Midge-rechts___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"headline":1102,"subline":1103,"description":1104,"text":1105,"images":1107,"files":1114},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1106},"\u003Cp>\u003Cstrong>MIDGE® features\u003C/strong>\u003C/p>\u003Cp>• no bacterial backbone sequences (e.g. ori, antibiotic resistance marker)\u003Cbr>• linear DNA fragment of minimal size\u003Cbr>• highly purified\u003Cbr>• reduced CpG content\u003Cbr>• improved safety\u003Cbr>• minimized side effects\u003C/p>\u003Cp>\u003C/p>",[1108,1111],{"url":1109,"alt":1110},"https://api.plasmidfactory.com/storage/115/responsive-images/MidgeAbfu%CC%88llung___webp_W___WIDTH____H.webp",{"de":7,"en":7},{"url":1112,"alt":1113},"https://api.plasmidfactory.com/storage/116/responsive-images/MIDGE-gru%CC%88n___webp_W___WIDTH____H.webp",{"de":7,"en":7},[],{"type":5,"title":1116,"slug":1118,"place":1120,"description":1121,"date":1122,"links":1123,"claim":1124,"content":1125},{"de":7,"en":1117},"McBox® Info Sheet",{"de":7,"en":1119},"mcbox-info-sheet",{"de":7,"en":7},{"de":1117,"en":1117},"2019-01-01",[],{"de":7,"en":7},[1126],{"headline":1127,"subline":1128,"description":1129,"text":1130,"images":1132,"files":1136},{"de":7,"en":1117},{"de":7,"en":7},{"de":7,"en":7},{"de":7,"en":1131},"\u003Cp>Download our McBox® Info Sheet.\u003C/p>",[1133],{"url":1134,"alt":1135},"https://api.plasmidfactory.com/storage/231/responsive-images/McBox-Flyer-pictur___webp_W___WIDTH____H.webp",{"de":7,"en":1117},[1137],{"file":1138,"title":1139},"https://api.plasmidfactory.com/storage/232/Flyer_McBox_1-stg._A4_-final.pdf",{"de":7,"en":1117},1776212106027]